Nos clients

Contents

Les societes biotechnologiques de France et leur annee de creation.

COMPANY    YEAR    LOCATION    BUSINESS MODEL    MANAGEMENT    FOCUS    STAGE   
Abcys 1999 IDF Design, Reagents Start-up | Cell Trade
Paris Key words: Immunology, Cytokines, Cell culture, Stem cells, Production, Distribution, Third Parties, Gemstem Managing Dir.-CEO: Martin (Thierry) [born 1961]
  Mission: to design, manufacture and distribute biotechnology reagents, and to develop own research on Stem Cells Sc.Dir.-CSO:
Clients: Research institutes, Hospitals, Universities, Pharmaceutical industry, Diagnostic industry Fin.Dir.-CFO:
www.abcysonline.com Age: 21 year(s) BusDev:
Financers (Hist.): undisclosed
Communication : no website corporate information or press release since 2006
AB Science 2001 IDF Discovery, Drugs Start-up | Cancers Clinical
Paris Key words: Mastocytosis, Inhibitors, Tyrosine Kinase, Anticancer, Inflammation, Auto-immune diseases Managing Dir.-CEO: Moussy (Alain) [founder, born 1965, MBA Wharton, ENSTA, ex-Carrefour (Dir M&A)]
  Mission: to develop innovative tyrosine kinase inhibitors for auto-immune diseases in man and animals Sc.Dir.-CSO:
Clients: Prescribers, Veterinarians Fin.Dir.-CFO: Guy (Laurent)
www.ab-science.com Age: 19 year(s) BusDev:
Financers (Hist.): privately owned (registered capital 2007 = 0.29 M€)
note (September 2011) : sales are derived from masitinib in veterinary practice
Adocia 2005 Rhône-Alpes Discovery, Drugs Personal venture | Multiple Clinical
Lyon Key words: Growth factors, Natural proteins, Regenerating organs, Osteoporosis, Diabetes, Aging population, BioChaperone Managing Dir.-CEO: Soula (Gérard) [born 1945, ex-Rhône Poulenc, Flamel Technologies (founder)]
  Mission: to develop innovative drugs for regenerating organs affected by diseases related to the aging of the population, such as osteoporosis and diabetes Sc.Dir.-CSO: Soula (Olivier) [born 1970, PhD polymer science, MBA-IAE (Lyon), ex-Flamel Technologies]
Clients: Pharmaceutical industry Fin.Dir.-CFO: Danaguezian (Valérie)
www.no-website.net Age: 15 year(s) BusDev: Soula (Rémi)
Financers (Hist.): AGF P.E., Bioam Gestion, Société Générale A.M., Viveris Management, Business angels (Alain Tornier and Jean Deléage [died in 2011]), InnoBio, SHAM (Société Hospitalière d’Assurances Mutuelles)
Advicenne Pharma 2007 Méditerranée Discovery, Drugs Personal venture | CNS Preclin
Castries Key words: CNS, Pediatry, Emergent diseases Managing Dir.-CEO: Granier (Luc-André) [founder, born 1954, Ph.D., M.D., ex-Forenap, Eli Lilly, Syntem]
  (near Nîmes) Mission: development and marketing of drugs for pediatric use mainly for the treatment of Central Nervous System Diseases (including autism, feeding behaviours dysfunctions and neurodegenerative disorders) Oper.Dir.-COO: Roussel-Maupetit (Caroline) [born 1969, Eng., ex-Syntem (co-founder), Protéine Performance]
Clients: undisclosed Sc.Dir.-CSO:
www.advicenne.com Age: 13 year(s) Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2007 = 0.13 M€), but CDC Entreprises with a board member
Communication : website under development (March, September 2011, October 2012)
Affichem 2002 Midi-Pyrénées Design, Drugs Start-up | Managing Dir.-CEO: Silvente (Stéphane) [co-founder, born 1968, MBA, Ms. International Business, also chairman] Cancers Preclin
Toulouse (also Design, Diagnostics) Sc.Dir.-CSO: Poirot (Marc) [co-founder, born 1960, also Inserm, Ph.D. chemical biology]
  Key words: Proteins, Dendrogenins, Cancer, Degenerative diseases Pharm.Dir.: Silvente-Poirot (Sandrine) [co-founder, also Inserm, Ph.D. molecular pharmacology]
Mission: to develop drug candidates based on proprietary new family of compounds derived from sterols, Dendrogenines A and B, in cancer and neurodegenerative diseases Fin.Dir.-CFO:
www.affichem.com Clients: Prescribers BusDev:
Age: 18 year(s) Financers (Hist.): privately owned, undisclosed (opening of capital proposed to individuals in 2012, up to 8.6%)
Agate Bioservices 2005 Méditerranée Contract, Services Personal venture | Target Preclin
Alès (also, Discovery, Targets) Managing Dir.-CEO: Chaabihi (Hassan) [founder, born 1962, Ph.D. molecular biology, ex-Protéines Performance, Quantum Biotechnologies]
  (near Nîmes) Key words: Gene expression, Protein production, Gene delivery, Insect cells expression, Baculovirus, BacTen Sc.Dir.-CSO: Chaabihi (Hassan)
Mission: to provide third parties with services ranging from gene cloning to protein (or virus) production (resp. purification), acting as a vector developer, either for protein production or for gene transfer, as well as a manufacturing partner, to to develop new systems and technologies in the gene expression, gene transfer and delivery areas Fin.Dir.-CFO:
www.agatebioservices.com Clients: Pharmaceutical industry, Biotech, Research labs BusDev:
Age: 15 year(s) Financers (Hist.): privately owned (registered capital 2006 = 0.008 M€)
Communication : no website news update since November 2006
Aisa Therapeutics 2005 IDF Discovery, Drugs Personal venture | Inflammation Preclin
Évry Key words: Vascular endothelium, Inflammation, Nanomolarity, Colitis, Cystic cancer, Nutraceuticals, Anti-stress Managing Dir.-CEO: d’Alessio (Patrizia) [founder, born 1952, M.D., Ph.D., ex-Inserm]
  (near Paris) Mission: to develop new anti-inflammatory molecules for rhumatoid arthritis, obesity, degenerative diseases, aging and metastatic spreading, based on the modulation-inhibition process in vascular permeability Sc.Dir.-CSO:
Clients: pharmaceutical industry, veterinary industry Fin.Dir.-CFO:
www.aisa-tx.com Age: 15 year(s) BusDev: Loumeau (Jean-François) [M.D., MBA]
Financers (Hist.): Critt Chimie, Anvar
Alfact Innovation 2006 IDF Discovery, Drugs Personal venture | Cancers Preclin
Paris Key words: Liver Failure, Liver Cancer Managing Dir.-CEO: Amouyal (Gilles) [born 1957, M.D., Ph.D.]
  Mission: to develop biopharmaceuticals for liver diseases Sc.Dir.-CSO: Bréchot (Christian) [M.D., Ph.D., V.P. Biomérieux, ex-Inserm]
Clients: undisclosed Oper.Dir.-COO: Mariau (Jérémie) [M.Sc. human genetic, Eng. Supagro]
alfactinnovation.com Age: 15 year(s) Fin.Dir.-CFO:
BusDev:
Financers (Hist.): unknown (registered capital 2008 = 1.48 M€)
Alizé Pharma 2007 Rhône-Alpes Discovery, Drugs Start-up | Multiple Preclin
Ecully Key words: Diabetes, Leukaemia, Recombinant L-asparaginase Managing Dir.-CEO: Abribat (Thierry) [co-founder, born 1964, Ph.D., Vet.D., ex-Sanofi-Recherche, Theratechnologies, OPi (CEO)]
  (near Lyon) Mission: to develop innovative therapeutics for the treatment of metabolic diseases and cancers (after early acquisition of products from Biotechs and in-house preliminary development) Sc.Dir.-CSO:
Clients: Pharmaceutical industry Fin.Dir.-CFO:
www.alz-pharma.com Age: 13 year(s) BusDev: Delale (Thomas)
Financers (Hist.): Octalfa (Gilles Alberici, board member), CEMA (Canada, André de Villers, board member), SHAM (registered capital 2007 = 0.052 M€)
Ambiotis 2007 Midi-Pyrénées Contract, Services (also, Research, Drugs) Personal venture | Inflammation Subcontractor
Toulouse Key words: Validation, Anti-inflammatory, Immunostimulatory, Biomarkers Managing Dir.-CEO: Dubourdeau (Marc) [founder, born 1973, M.D., Ph.D. immunology, Ms. Management (Toulouse)]
  Mission: to provide preclinical testing services (cellular and animal experiments) for anti-inflammatory and immunostimulatory assays of third parties, and to undertake own research specialized in the study of lipoxins, resolvins and protectins Sc.Dir.-CSO: Dubourdeau (Marc)
Clients: Pharmaceutical industry, Cosmetics, Nutraceutics, Agro-food Fin.Dir.-CFO:
www.ambiotis.com Age: 13 year(s) BusDev:
Financers (Hist.): privately owned (registered capital 2007 = 0.04 M€)
Anaconda Pharma 2003 IDF Discovery, Drugs Spin-off | Cancers Preclin
Paris Key words: Protein interactions, Condyloma, Anti-viral Managing Dir.-CEO: Blumenfeld (Marta) [born 1955, Ph.D. Biochemistry, ex-Genset]
  Mission: to develop a proprietary platform for the discovery of small molecules that disrupt protein:protein interactions, as a distinct unexploited class of pharmaceutical targets, due to the difficulty of recognizing drugable hot-spots on the surface of interacting proteins Sc.Dir.-CSO:
Clients: Prescribers Med.Dir.: Compère (Delphine) [Ph.D. organic chemistry, ex-Pfizer, Cerep]
www.anacondapharma.com Age: 17 year(s) Fin.Dir.-CFO: Bali (Ismahane) [Ms accounting, ex-Audit and Diagnostic]
BusDev:
Financers (Hist.): privately owned (private investors)
Aptys Pharmaceuticals 2002 Centre Contract, Research Spin-off | Multiple Preclin
Clermont-Ferrand (also, Delivery, Drugs) Managing Dir.-CEO: Boutignon (François) [co-founder, born 1960, Ph.D. protein biochemistry, ex-Europeptides]
  Key words: Formulation, Peptides, ADHAPT, Bi-Gel, Generic Plus, Insulin delivery Sc.Dir.-CSO: Boutignon (François)
Mission: to develop formulation of new chemical entities and peptides/proteins, reformulation of registered molecules and novel drug delivery systems for third parties, to develop internal research programs for own technological portfolio, based on subcontractor cash flow Techn.Dir.-CTO: Barres (Thomas) [Ms.Sc., Pharm. D., ex-LPH Industries]
www.aptys-pharmaceuticals.com Clients: Pharmaceutical industry, Biotechs Fin.Dir.-CFO:
Age: 18 year(s) BusDev:
Financers (Hist.): Sofimac Partners, Crédit Agricole Centre France, privately owned (registered capital 2007 = 0.10 M€)
Ariana Pharmaceuticals 2003 IDF Contract, Knowledge Spin-off | Data Subcontractor
Paris Key words: Discovery acceleration, Virtual screening, Knowledge management, Decision support, KEM, eADMET, Bioassays Managing Dir.-CEO: Afshar (Mohammad) [co-founder, born 1966, Ph.D. biochemistry, ex-RiboTargets]
  Mission: to provide decision-support tools, in order to accelerate drug discovery of third parties Sc.Dir.-CSO:
Clients: Pharmaceutical industry, Biotechs Tech.Dir.-CTO: Kuras (Mariana) [Ph.D. biophysics, ex-Biosystems, Pfizer]
www.arianapharma.com Age: 17 year(s) Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned, Institut Pasteur, Vizille Capital Innovation
Aterovax 2006 IDF Discovery, Development, Diagnostics and Immunology-vaccines Start-up | Cardiovasc 1st product soon available
Paris Key words: Tests, Atherosclerosis, sPLA2 Activity Test, Atherosclerosis Risk Assessment, Biomarker for Cardiovascular Risk Evaluation and Prevention, Secreted Phospholipase A2 Activity, In Vitro Diagnostic Assay, Immunotherapy Managing Dir.-CEO: Surun (Dominique) [M.D., MBA (CPA), ex-Meda Pharma, Janssen Cilag, 3M]
  Mission: to develop innovative solutions to predict, diagnose, prevent and treat cardiovascular diseases through a proprietary understanding of atherosclerosis Sc.Dir.-CSO: Valentin (Emmanuel) [Ph.D.]
Clients: undisclosed Fin.Dir.-CFO:
www.aterovax.com Age: 14 year(s) Regul.Dir.: Doceur (Paula) [Ph.D.]
BusDev:
Financers (Hist.): SGAM (registered capital 2008 = 0.123 M€)
Communication : website under re-construction (October 2012), legal undetailed changes at the end of 2011 – beginning 2012 (new chairman of the board, capital increase)
Atlantic Bone Screen 2005 Bretagne Contract, Services Personal venture | Inflammation Subcontractor
Nantes Key words: Validation, In-vivo testing, Osteo-articular pathologies, LPRO Managing Dir.-CEO: Le Bot (Ronan) [co-founder, born 1977, Pharm.D.]
  Mission: to offer in vitro and in vivo (patented animal models) services dedicated to validation of proof of concept in osteoarticular pathologies, and (Atlanchim) to act as a subcontractor for the synthesis of new molecules Sc.Dir.-CSO:
Clients: Pharmaceutical industry, Biotechs, Chemical industry, Food industry Fin.Dir.-CFO:
www.atlantic-bone-screen.com Age: 15 year(s) BusDev: Porcher (Elisabeth) [MBA, ex-Eurocopter]
Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€), internal growth (no outside investors searched)
Aureus Sciences 2000 IDF Contract, Knowledge Start-up | Data Subcontractor
Paris Key words: Bioinformatics, Knowledge management, Molecular modeling, Data structuring, AurSCOPE, AurPROFILE Managing Dir.-CEO: Theodosiou (Jason) [born 1959, Ph.D. organic chemistry, MBA Sup de Co Paris, ex-MDL Information Systems, EMAX/SciQuest, LION Bioscience, Elsevier
  Mission: to provide knowledge management solutions to accelerate life science discovery for third parties Sc.Dir.-CSO:
Clients: Pharmaceutical industry, Biotechs Dev.Dir.: Barberan (Olivier) [Ph.D.]
www.aureus-sciences.com Age: 21 year(s) Fin.Dir.-CFO:
MktgComm:
BusDev:
Financers (Hist.): Bioam, AXA, FCJE (CDC), Matignon, OTC-AM
Note : the news thread astutely mixes own events and general R&D major findings external to the company
B Cell Design 2008 Centre Discover, Drugs Personal venture | Cancers Proof-of-Concept
Limoges Key words: Humanised antibodies Managing Dir.-CEO: Sainte-Laudy (Jean) [born 1946, Ph.D. immunology, ex-Pasteur Cerba]
  Mission: to develop, manufacture humanised IgA and IgG antibodies from genetically modified mice Sc.Dir.-CSO: Cuvillier (Armelle) [Ph.D. health biology]
Clients: Clinical labs, Research labs, Medical imaging, Therapists Techn.Dir.-CTO: Champier (Gaël) [M.S. biotechnologies]
www.b-cell-design.com Age: 13 year(s) Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Limousin Participation, Limousin Expansion, Limousin Business Angels
BioAlliance Pharma 1997 IDF Discovery, Drugs Start-up | Cancers Launch
Paris (also Delivery, Drugs) Managing Dir.-CEO: Greciet (Judith) [Pharm.D., ex-Eisai, Wyeth, LFB, Zeneca, Pharmacia]
  Key words: Cancer, HIV, Opportunistic infections Oper.Dir.-COO:
Mission: to discover, develop and market innovative treatments rapidly evolving therapeutic markets -cancer, serious viral diseases (such as HIV) and opportunistic infections- with NCE’s ans drug delivery improvements Med.Dir.-CMO: Attali (Pierre) [M.D., M.Sc., ex-Synthelabo, Sanofi, OSMO (co-founder), Molecular Engines Laboratories, Urogene]
www.bioalliancepharma.com Clients: Prescribers Sc.Dir.-CSO: Kayitalire (Louis) [M.D., Institut Gustave Roussy, ex-Eli Lilly, B.M.S., Cephalon]
Age: 23 year(s) Fin.Dir.-CFO: Fellman (Nicolas) [MBA, ex-Pfizer, Ernst & Young]
SalesMktg: Dupré (Florence)
BusDev:
Financers (Hist.): 3i, Auriga Partners, ING, Capricorn Venture, ABN-AMRO, SPEF Ventures, AGF P.E., Public
Note : Financière de la Montagne (a company of family Besançon-Trébouta, previously holding Laboratoires Delagrange, part of Synthelabo, acquired by Sanofi) holds 10% of capital in December 2012
Biocortech 2001 IDF Discovery, Drugs Spin-off | CNS Preclin
Paris Key words: Neuro-psychiatric diseases, Biomarkers, Serotonin, Glutamate Managing Dir.-CEO: Weissmann-Pujol (Dinah) [co-founder, born 1951, Pharm.D., Ph.D. neurobiology, ex-Roussel Uclaf, CNRS]
  Mission: to develop novel biomarkers and treatments for psychiatric disorders, including depression, bipolar disorders, schizophrenia, and cognitive deficits Sc.Dir.-CSO: Pujol (Jean-François) [co-founder, M.D., Ph.D., Hospital Professor, ex-Roussel Uclaf, INSERM and CNRS]
Clients: Pharmaceutical industry (own development, up to clinical trials) Fin.Dir.-CFO:
www.biocortech.com Age: 19 year(s) BusDev: Allemand (Frédéric) [M.D. cardiology, ex-Hybrigenics, Bayer, Syngenta, Biovector Therapeutics, Hybrigenics, Genopole Entreprises, Medincell, Surfactis, Phenopro]
Financers (Hist.): Institut Pasteur, business angels
BioCydex 2002 Aquitaine Delivery, Drugs Personal venture | Ophthamo Preclin
Poitiers (also, Contract, Services) Managing Dir.-CEO: Belgsir (El Mustapha) [co-founder, born 1958, Ph.D., ex-CNRS]
  Key words: Ophthalmology, Cyclodextrins Sc.Dir.-CSO: Cenatiempo (Yves) [co-founder, also board chairman till 2008, born 1950, Prof. biochemistry (Poitiers)]
Mission: to develop new compound formulations in ophthalmology, cancerology, and organ preservation during transplantation Fin.Dir.-CFO: Marembaud (Olivier) [born 1952, Engineer, ex-Frantour, Kelois, SNCF]
www.biocydex.com Clients: Pharmaceutical industry (up to clinical stage) BusDev:
Age: 18 year(s) Financers (Hist.): Oseo
Biométhodes 1997 IDF Contract, Manufacturing Personal venture | Haemophilia Trade
Évry (also Design, Drugs) Managing Dir.-CEO: Amsallem (Gilles) [born 1954, ex-Mixis Genetics, Avesthagen (India), Dupont, Sorin Biomedica, Eurobio]
  (near Paris) Key words: Protein engineering, Mutagenesis, Enzymes, Service Contracts, Haemophilia, High throughput screening, Manufacturing processes, THR selection scheme Sc.Dir.-CSO: Winter (Bruno) [Ph.D., ex-AB Enzymes]
Mission: to provide third parties with industrial processes based on proprietary know-how on improved enzymes, and to develop a next generation biologicals, with an initial focus on haemophilia, from sister company platform, Biométhodes Therapeutics Techn.Dir.-CTO: Langvad (Niels) [ex-Biodiesel (co-founder)]
www.biomethodes.com Clients: Pharmaceutical Industry, Biotechs, Chemical industry, Animal food Fin.Dir.-CFO: Kazandjian (Raffy) [ex-CDC-Innovation Partners]
Age: 23 year(s) BusDev:
Financers (Hist.): CDC Innovation, CIC Capital, FCJE (CDC)
Biom’up 2005 Rhône-Alpes Development, Biomaterials & Medical devices Spin-off | Collagen Trade
Saint-Priest (also, Contract, Manufacturing) Managing Dir.-CEO: Picot (Sylvain) [co-founder, born 1978, Ph.D., Insa],
  (near Lyon) Key words: Devices, Collagen, Glycosaminoglycans, Biopolymers, Grafting, Human reconstruction Sc.Dir.-CSO: Forest (Patricia) [co-founder, born 1978, Ph.D., Insa], also COO]
Mission: to develop and manufacture innovative biopolymers, such as collagens, for implantable Medical Devices, with a special focus on long term applications, and to design customized Purification Tools, particularly in affinity chromatography Fin.Dir.-CFO:
www.biomup.com Clients: Pharmaceutical industry, Cosmetic industry, Biotechs SalesDir.: Francy (Philippe) [Sup de Co]
Age: 15 year(s) Financers (Hist.): privately owned, Créalys, SHAM, Sofimac Partners, Ameliane, Aquasourça, InnoBio, Viveris Management, OTC Asset Management
BioProtein Technologies 1998 IDF Contract, Manufacturing Personal venture | Multiple Preclin
Jouy-en-Josas Key words: Therapeutic proteins, Gene expression, Transgenic rabbits Managing Dir.-CEO: Lignel (Jean)
  (near Paris) Mission: to provide third parties with production of recombinant therapeutic proteins and vaccines in the milk of transgenic rabbits, as a fully integrated service from gene expression to industrial production of purified proteins and vaccines Sc.Dir.-CSO: Ripoll (Pierre-Jean) [Ph.D., ex-Aventis, Biogemma]
Clients: Pharma industry, Research labs, Biotechs Fin.Dir.-CFO:
www.bioprotein.com Age: 22 year(s) BusDev: Fouassier (Alexandre) [Eng. INRA, M.Sc. biochemistry, also COO]
Financers (Hist.): Société Générale A.M., Gilde, Creagro, Iwic, Anvar
BioQuanta 2003 IDF Contract, Research Personal venture | Cancers Patents
Paris (also, Discovery, Drugs) Managing Dir.-CEO: Rabeuf (Rémi) [M.Sc. biology, MBA, ex-Roche (20 years)]
  Key words: Clinical biology, Biochemistry, Molecular modeling, In-silico Toxicity Prediction, In-vitro metabolic Exploration, Diagnostic kit and drug development Sc.Dir.-CSO:
Mission: to promote predictive and personalized medicine Oper.Dir.-COO:
www.bioquanta.com Clients: Biotech companies, Pharmaceutical, Food and Cosmetics industries Fin.Dir.-CFO:
Age: 17 year(s) BusDev: Guidon (Romain) [MBA]
Financers (Hist.): privately-owned (undisclosed private investors)
BioSystems International 2004 IDF Design, Diagnostics Spin-off | Multiple Trade
Évry Key words: Biomarkers, Drug discovery improvement, Development productivity, Serum proteins Managing Dir.-CEO: Tirouflet (Jean-Pierre) [born 1950, ENA, ex-Rhodia (President), MEDEF, Rhône-Poulenc, Finance Ministry, Crédit National Bank
  (near Paris) Mission: to discover and validate biomarkers through partnerships with pharmaceutical, biotechnology and diagnostics companies and in-house research programs or academic collaborations Sc.Dir.-CSO: Takacs (Laszlo) [co-founder, born 1955, M.D., Ph.D., ex-Pfizer, Parke Davis, Amgen, NIH]
Clients: Pharmaceutical industry (AstraZeneca), Biotechs Tech.Dir.-CTO: Guttman (András) [co-founder, Ph.D. Chemistry, ex-Beckman Coulter]
www.biosys-intl.com Age: 16 year(s) Fin.Dir.-CFO: Hollai (Andrea) [MBA, ex-Hungarian Journalist’s Federation]
BusDev:
Financers (Hist.): Société Générale
Note : a susidiary (research) in Hungary
BMSystems (Bio-Modeling) 2004 IDF Discovery, Hub Start-up | Multiple Proof-of-Concept
Paris Key words: Models, Proof of concept, Predictive efficacy, Validation, Spin-off Managing Dir.-CEO: Géa (Manuel) [co-founder, born 1960, Eng. Centrale, ex-Hemispherx (CEO), Boehringer-Ingelheim, Colgate-Palmolive, McKinsey]
  Mission: to help clients run their life sciences R&D programs better, faster, cheaper and safer by applying CADI methodologies and tools, an operational systems biology approach (mainly in the fields of infectious diseases, neurology, psychiatry, oncology, dermatology and innovative bioprocesses) Sc.Dir.-CSO: Iris (François) [also board chairman, born 1950, Ph.D., ex-Valigen (co-founder), Millenium]
Clients: R&D departments (on a partnering basis), Financers (in case of spin-off) Med.Dir.-CMO: Dine (Gérard) [M.D., Ph.D.]
www.bmsystems.net Age: 16 year(s) I.T.Dir.-CIO: Santamaria (Pablo) [Eng. Centrale, ex-Formitel, Glaxo]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately-owned (no search for external investors)
Carmat 2008 IDF Development, Device Spin-off | Cardiovasc Preclin
Vélizy Key words: Artificial heart, Computer simulation, Electronic captors, Bioprothesis Managing Dir.-CEO: Conviti (Marcello) [born 1952, Ph.D., MBA, ex-Edwards Lifesciences, Sorin]
  (near Paris) Mission: to clinically develop, then market a fully implantable artificial heart for patients suffering in the aftermath of a massive heart attack or with late-stage heart failure and for whom standard drug therapy, ventricular assistance and/or a heart transplant have failed or are not possible Sc.Dir.-CSO: Carpentier (Alain) [born 1933, co-founder, M.D. (surgery), Hospital Professor]
Clients: Hospitals Fin.Dir.-CFO:
www.carmatsas.com Age: 12 year(s) MktgComm: Leroy (Valérie) [Ms. Mktg (Paris), ex-Toshiba Systèmes, Medtronic, Edwards Lifesciences]
BusDev:
Financers (Hist.): Truffle Capital, Oseo, EADS
Note : company first sourced as a J.V. Carpentier-Matra, in 1993 (company name, Carmat = Carpentier + Matra)
Note : Internet showroom, available since June 2009
Cellectis 2000 IDF Discovery, Therapy Spin-off | Genome Preclin
Romainville (also Research, Subcontractor) Managing Dir.-CEO: Choulika (André) [co-founder, born 1965, Ph.D. virology], also chairman
  (near Paris) Key words: Genomic engineering, Meganuclease Recombination Systems (MRS), Proteins, DNA-repair Oper.Dir.-COO: Simon (Mathieu) [M.D., ex-Wyeth, Pierre Fabre]
Mission: to research in, develop and market rational genome engineering technologies with 3 focus, manufacturing of proteins for therapeutic purposes, improvement of seed characteristics and development of treatments against single-gene disorders (myopathies, sickle-cell anaemia, etc.) and against the infections by DNA viruses (herpes, viral hepatitis, HIV, etc.) Sc.Dir.-CSO: Duchateau (Philippe) [Ph.D. science]
www.cellectis.com Clients: Pharmaceutical industry, Biotechs, Agro industry, Research labs Tech.Dir.-CTO: Epinat (Jean-Charles) [Ph.D. science, ex-Institut Pasteur]
Competitors: Applied Biosystems, 454 Life Sciences, Celera Fin.Dir.-CFO: Schwich (Pierre) [École des Mines (Paris), ex-Corning, Danone, Hewlett-Packard, 3i, Siparex, Next Venture)]
Age: 21 year(s) BusDev: Sourdive (David) [co-founder, Ph.D. virology, Polytechnique, ex-CEO]
Lic.Dir.-CBO: Pollet (Dirk) [Ph.D. biochemistry (Antwerp), ex-Dircs Consultant, Galapagos, Glaxo Welcome, Innogenetics]
Comm.Dir.: Delassus (Sylvie) [Polytechnique (1983), Ph.D., ex-Institut Pasteur, Aventis]
Financers (Hist.): Kaminvest, BankInvest, AGF P.E., Odyssée, Edmond de Rothschild, FSI, Bastid, Public
Note: website revamping, in September 2010
note : the company has created a plant division in 2011, as a major diversification
Cellial Technologies 2001 North-Picardie Contract, Research Personal venture | Multiple Subcontractor
Lens Key words: CNS research optimization, In vitro cell culture, Blood-Brain Barrier Managing Dir.-CEO: Leman (Sandrine) [born 1971, Ph.D., Institut Pasteur]
  Mission: accelerate CNS profiling and identify qualified leads candidates and eliminates the botleneck of drug transport accross Blood-Brain Barrier from clients’ discovery process Sc.Dir.-CSO: Berezowski (Vincent) [Ph.D.]
Clients: Pharmaceutical industry, Biotechs, Academic labs Fin.Dir.-CFO:
www.cellial.com Age: 20 year(s) BusDev:
Financers (Hist.): Finorpa, Nord Innovation, Innovam
Note : 2 additional round-table financing in 2007 and 2008 of undisclosed amount
CellProthera 2008 Alsace Discovery, Devices Personal Venture | Cardiovasc Proof-of-Concept
Mulhouse Key words: Cell Therapy, Regeneration, Myocardial tissue Managing Dir.-CEO: Lataste (Xavier) [born 1949, Ph.D. clinical neurochemistry, M.D., ex-Sandoz, Novartis]
  Mission: to develop innovative stem cell therapy for the regeneration of myocardial tissue, allowing prevention of chronic heart failure after myocardial infarction Sc.Dir.-CSO: Hénon (Philippe) [founder, born 1938, M.D. Hematology, IRHT (founder, 1987), University Prof., also Board Chairman]
Clients: not disclosed Oper.Dir.-COO: Jelsch (Jean-Claude) [CNAM, MBA (CPA, Lyon), ex-Ecco, Adecco]
www.cellprothera.com Age: 12 year(s) Med.Dir.-CMO : Lataste (Xavier)
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned, Financière Bendelé, Alsace Business Angels (registered capital 2008 = 0.05 M€)
CellVax 2001 IDF Contract, Services Personal venture | Cancers Subcontractor
Évry Key words: Preclinical validation studies, Cancer, Viral diseases, Nodule, Angiogenesis model Managing Dir.-CEO: Wei (Ming) [co-founder, born 1963, Ph.D. molecular biology]
  (near Paris) Mission: to provide third parties with complete preclinical innovating services allowing to accelerate the drug development process in oncology field Sc.Dir.-CSO: Wei (Ming)
Clients: Pharmaceutical industry, Biotechs, Public-sector labs (up to phase II) Med.Dir-CMO: Schatz (Christian) [M.D., Pharm.D., ex-Transgène]
www.cellvax-pharma.com Age: 19 year(s) Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€)
Notes : website again active in 2010 ; no press release (or news) since 2007
Cerenis Therapeutics 2004 Midi-Pyrénées Discovery, Drugs Personal venture | Cardiovasc Clinical
Labège Key words: HDL therapy, Cholesterol, Atherosclerosis, Cardiovasculars Managing Dir.-CEO: Dasseux (Jean-Louis) [co-founder, born 1958, Ph.D., MBA, ex-Esperion Therapeutics (Pfizer), Fournier]
  (near Toulouse) Mission: to discover, develop and market next generation HDL therapies Oper.Dir.-COO: Brinkerhoff (William) [co-founder, MBA, ex-Esperion Therapeutics (Pfizer), Sankyo]
Clients: Prescribers Sc.Dir.-CSO: Lalwani (Narendra D.) [Ph.D., MBA, ex-Parke Davis, Esperion, Pfizer]
www.cerenis.com Age: 16 year(s) Fin.Dir.-CFO: Tupin (Cyrille) [CPA, ex-Sygnatures, PricewaterhouseCoopers]
Med.Dir.-CMO: Paolini (John F.) [M.D., Ph.D., ex-Merck US, Bayer]
BusDev: Brya (Tom) [MBA (Northwestern), MST, CPA, ex-Pharmacia, Monsanto/Searle, Cardinal Health, KV Pharmaceutical]
Financers (Hist.): Sofinnova, HealthCap, Alta Partners, EDF Ventures, NIF Ventures, Daiwa Corporate Investment, TVM Capital, OrdiMed, FSI, Irdi-IXO
CliniGenetics 2000 Méditerranée Discovery, Drugs Personal venture | Cardiovasc Preclin
Nîmes Key words: Atherothrombosis, Atherix pig model, Alive bio-informatics Managing Dir.-CEO: Falco (Jean-Louis) [born 1949, also board chairman, DEA Mkg-Finance Dauphine, ex-Schneider, Aurex (own consulting company)]
  Mission: to discover new therapeutics for the treatment of cardiovascular, cerebrovascular and lower limb ischemic diseases with a specific emphasis on atherothrombosis Sc.Dir.-CSO: Marguerie de Rotrou (Gérard) [born 1940, Ph.D., ex-Inserm, CEA, University Professor in Functional Genomics]
Clients: Prescribers Fin.Dir.-CFO:
www.clinigenetics.com Age: 20 year(s) BusDev:
Financers (Hist.): BankInvest
Notes (February 2012) : the company website is unavailable and the URL does not exist any more since 2010, but a legal process with board meeting occurred in August 2010 (still the same, in September 2011) and a board meeting occured in December 2011 and an AGM in August 2012
Covalab 1995 Rhône-Alpes Design, Drugs Personal venture | Multiple Trade
Villeurbanne (also Design, Diagnostics) Managing Dir.-CEO: El Alaoui (Saïd) [born 1955] & Thomas (Vincent) [born 1957]
  (near Lyon) Key words: Immunochemistry, MABs, Polyclonal antibodies Sc.Dir.-CSO:
Mission: to supply innovative and unique polyclonal and monoclonal antibodies to third parties, such as universities, research institutes and commercial organisations around the world Fin.Dir.-CFO:
www.covalab.com Clients: Research labs BusDev:
Age: 25 year(s) Financers (Hist.): privately owned (registered capital 2007 = 0.24 M€)
Communication: no website corporate news since 2005
Cytheris 1999 IDF Discovery, Immunology Personal venture | Cancers Clinical
Issy-les-Moulineaux Key words: Immune modulation, Cancer, HIV, HCV, Recombinant interleukin Managing Dir.-CEO: Marron (Damian) [born 1962, Pharmacologist, ex-3M Pharma, Orphan Europe, Rhône Poulenc Rorer, Glaxo, Nicox, Trophos]
  (near Paris) Mission: to discover and develop new therapies for immune modulation, by reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV and HCV, or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT) Sc.Dir.-CSO:
Clients: Prescribers Fin.Dir.-CFO: Vannier (Bertrand)
www.cytheris.com Age: 22 year(s) BusDev: Keatinge (Richard W.) [ex-BioAlliance Pharma]
Financers (Hist.): Bioam, GestionT2C2/Bio, CDP Capital Technology Ventures, AXA P.E., Crédit Agricole P.E., CDC Innovation, Forbion, Caisse de dépôt et placement du Québec (Canada) (registered capital 2006 = 52.5 M€)
Cytoo 2008 Rhône-Alpes Contract, Research Personal venture | Consumables Trade
Grenoble Key words: Adhesive micropatterns, High Content Analysis, Cell based assays, Cell Screening Managing Dir.-CEO: Chatelain (François) [co-founder, born 1965, ex-CEA, Protogene, Life Technologies, Genset, DNAgency]
  Mission: to develop, manufacture, and distribute products that make cellular analysis robust and reliable by drastically decreasing cell variability Sc.Dir.-CSO: Bornens (Michel) [co-founder, board member, ex-Pasteur Institute, Curie Institute]
Clients: Pharmaceutical industry Oper.Dir.-COO: Fuchs (Alexandra) [co-founder, born 1969, Ph.D. biochemistry, Eng. Centrale, ex-CEA]
www.cytoo.com Age: 12 year(s) Fin.Dir.-CFO: Fayand (Laurence) [EM-Lyon (MBA), ex-Fideco, Hewlett-Packard, Alditech, Crocus Technology (co-founder), Beamind]
BusDev: Sharp (William) [also President-CEO Cytoo Inc.]
Financers (Hist.): privately owned (registered capital 2008 = 0.1 M€), Auriga Partners, CEA Valorisation, Rhône-Alpes-Création, Expansinvest, Jacques Lewinern, Sham and Entrepreneurs Fund
DBV Technologies 2002 IDF Discovery, Diagnostics, Immunotherapy Start-up (speciality pharma company) | Allergy Trade
Boulogne Billancourt Key words: Allergies, Viaskin, Epicutaneous Immunotherapy, Diallertest Managing Dir.-CEO: Benhamou (Pierre-Henri) [born 1955, M.D. Paediatrics]
  (near Paris) Mission: to develop an innovative non invasive delivery technology, Viaskin, worldwide patented, suitable for severe allergic patients to food allergy both in diagnosis and specific epicutaneous immunotherapy (EPIT) Sc.Dir.-CSO: Benhamou (Pierre-Henri) (also, CEO) & Dupont (Bertrand) [Ensam]
Clients: Pharmaceutical industry, Food industry, Cosmetics Pharm.Dir.: Martin (Laurent) [Pharm.D., MBA IAE Paris, ex-Orphan Europe, Galderma, Fournier, Guerbet]
www.dbv-technologies.com Age: 18 year(s) Clin.Dir: Agbotounou (Wence) [Ph.D. pharmacology, MBA ESCP, ex-Quintiles, PRA International]
Fin.Dir.-CFO: Schilansky (David) [Dauphine University, Imperial College London, ex-Ipsen, UBS Warburg, Thomson]
Dvpt. Dir: Ruban (Charles) [ex-Stallergènes, Europgroup Centrale (Lyon), Ms.Sc, Biomedical Engineering (Harvard-M.I.T), MBA (INSEAD)
BusDev:
Financers (Hist.): Cap Décisif, Créagro, Sofinnova Partners, Apax Partners, ALK-Abello (Pharma company), InnoBio, Lundbeckfond Ventures, Shire, Alto Invest, Fonds Stratégique d’Investissement (FSI), Public
Diaxonhit 1997 IDF Discovery, Diagnostics Personal venture | Genome Trade
Paris (also, Discovery, Drugs) Managing Dir.-CEO: Maurel (Loïc) [M.D., ex-Debiovision, Novartis, Rhône Poulenc Rorer]
  Key words: RNA splicing, Gene profiling technology, Cancer, Alzheimer Sc.Dir.-CSO: Pando (Matthew) [Ph.D. molecular biology]
Mission: to leverage on alternative RNA splicing, the process by which a single gene can lead to several proteins in the fields of drug discovery, diagnostics and biochips and to sell proprietary gene profiling technology named Datas in order to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease Fin.Dir.-CFO: Duchesne de Lamotte (Hervé) [MBA, Ms (MIT), ex-Stanford Research Institute, AT Kearney France, IDM, Cirrus Finance Management]
www.diaxonhit.com Clients: Pharmaceutical industry (own development up to phase II) C.O.O.: (Diagnostics Division) Barber (Isabelle) [Ph.D. organic chemistry, ex-Isis Pharmaceuticals, Genset, Ortho Clinical Diagnostics (J&J)]
Age: 23 year(s) C.O.O.: (Therapeutic Division) Pando (Matthew) [Ph.D. molecular biology]
BusDev:
Comm.Dir.: Hoff (Corinne) [ex-Nicox, Aventis, Novartis)]
Financers (Hist.): CDC Innovation, Sofinnova, Oxford Bioscience Partners, AGF P.E., BNP P.E., Dresdner Kleinwort, Danske Bank, LCF Ed. de Rotschild, Sudinnova, Biomérieux (5.8%, end 2007), Public
DNA Therapeutics 2006 IDF Discovery, Drugs Personal venture | Cancers Preclin
Évry Key words: Cancer, siDNA, DNA repair Managing Dir.-CEO: Sun (Jian Sheg) [born 1959, also board chairman, Ph.D.]
  (near Paris) Mission: to develop proprietary siDNA (signal interfering DNA) technology platform and molecules, interfering with DNA damage repair mechanisms, to fight treatment-resistant cancers Sc.Dir.-CSO: Sun (Jian Sheg)
Clients: Prescribers Res.Dir.: Dutreix (Marie) [Ph.D, CNRS (Institut Curie)]
www.dna-therapeutics.com Age: 14 year(s) Fin.Dir.-CFO: Cervera (Bruno) [also, Actinnov (CEO), ex-Neurotech]
BusDev:
Financers (Hist.): Blue Medical Investment, Inserm Transfert
Domain Therapeutics 2001 Alsace Discovery, Drugs Personal venture | CNS Clinical
Illkirch Graffenstaden Key words: Neurological disorders, Neurotransmitter modulation, GPCR, Neuroclide, Glutamate inhibitor, Utrophin inducer, Parkinson, Alzheimer, Schizophrenia, Diabetes Managing Dir.-CEO: Neuville (Pascal) [co-founder, born 1964, Ph.D. molecular biology, ex-Transgene, Assistant Professor]
  (near Strasbourg) Mission: to discover and develop new treatments notably (but not only) for neurological and metabolic disorders, with an exclusive focus on GPCR-mediated neurotransmitter modulation Sc.Dir.-CSO: Neuville (Pascal) & Bossi (Laura) [M.D. neurologist, ex-Sanofi, Synthélabo]
Clients: Prescribers Pharmas and Biotechs (own development up to phase III Preclinical candidate) Fin.Dir.-CFO:
www.domaintherapeutics.com Age: 19 year(s) BusDev:
Financers (Hist.): Sofinnova Partners, Auriga Partners, La Compagnie Financière de Rothschild, Siparex, AGF P.E., FCJE, Airfi (Alsace Inter Regio Fonds d’Investissement) and Alsace Création, plus Sam Eletr and Bernard Gilly
Communication: the company was named Faust Pharmaceuticals from inception till December 2008, with URL as www.faustpharma.com
Dynabio 1992 Méditerranée Design, Diagnostics Personal venture | Multiple Preclin
Marseille Key words: Stress proteins, Pancreatitis-Associated Protein (PAP), PancrePAP kit Managing Dir.-CEO: Broto (Ruben) [born 1937]
  Mission: to develop new immunological tools to improve detection of Pancreatitis-Associated Protein (PAP), as a new class of stress proteins whose expression reflects with extreme sensitivity pathological alterations of several tissues in the gastrointestinal tract Sc.Dir.-CSO:
Clients: Research labs Oper.Dir.: Slagel (Dean) [born 1970]
www.dynabio.com Age: 28 year(s) Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned
Communication: no website news update since 2006, extremely limited media information since inception
Edelris 2005 Rhône-Alpes Contract, Research Spin-off | Multiple Subcontractor
Lyon Key words: Screening, Medicinal chemistry, Small molecules, Mimetics, CombiChem Managing Dir.-CEO: Ortholand (Jean-Yves) [co-founder, born 1965, Ph.D., ex-Bayer, Rhône Poulenc Santé, Merck Santé]
  Mission: to design and produce innovative, therapeutically relevant, natural-mimetic screening compounds, in order to accelerate the hit-lead discovery process in pharmaceutical and biotech research organizations Sc.Dir.-CSO: Greiner (Alfred) [co-founder, Ph.D., ex-Rhône Poulenc]
Clients: Pharmaceutical industry Fin.Dir.-CFO:
www.edelris.com Age: 15 year(s) BusDev:
Financers (Hist.):
Note: no legal accounting report since 2005
Endotis Pharma 2003 IDF Discovery, Drugs Start-up | Multiple Preclin
Romainville Key words: Small-glyco drugs (SGD), Thrombosis, Cancer Managing Dir.-CEO: Woller (Charles) [born 1949, M.D., Ph.D. Clinical pharmacology, MBA, ex-Neuro3D (founder), Cadus, Roche France (Managing Director), Warner Lambert, Akzo]
  (near Paris) Mission: to discover and develop Small-glyco drugs (SGD) for application in thrombosis and oncology Sc.Dir.-CSO: Petitou (Maurice) [Ph.D., ex-Sanofi, Lauréat Prix Charles Mentzer 2009]
Clients: Prescribers Fin.Dir.-CFO: Degove (Stéphane) [Sup de Co (Paris), ex-Sanofi, Orica, OC&C]
www.endotis.com Age: 17 year(s) BusDev: Henrard (Denis) [Ph.D. biochemistry , also DHC, ex-BD Medical, Elixir Pharmaceuticals, Johnson & Johnson, Abbott]
Financers (Hist.): Endeavour Vision, NIF SMBC Ventures, Sofinnova Partners
Epixis 2003 IDF Discovery, Immunology Personal venture | Virus Preclin
Paris Key words: Flu, C-Hepatitis, Mimetic particles, Virus-like particle vaccines Managing Dir.-CEO: Dalba (Maria) [born 1967, M.D., Ph.D.]
  Mission: to develop a platform technology for a new generation of Virus-Like Particle vaccines (eVLP) that may allow to quickly manufacture seasonal or pandemic flu vaccines, to treat Hepatitis C, and to be applied to other infectious diseases, such as HPV or HIV Sc.Dir.-CSO:
Clients: Pharmaceutical industry Fin.Dir.-CFO:
www.epixis.com Age: 17 year(s) BusDev:
Financers (Hist.): Génopole 1er Jour
ERYtech Pharma 2004 Rhône-Alpes Delivery, Drugs Personal venture | Cancers Clinical
Lyon Key words: Encapsulation, Red blood cells, Cancer, Cleav’Ery, Oxygen’Ery, Deliv’Ery, Vaccin’Ery, Graspa Managing Dir.-CEO: Beyen (Gil) [M.Sc. Bioengineering (Belgium), MBA, ex-TiGenix, Arthur D. Little] and Goineau (Pierre-Olivier) [co-founder, born 1967, MBA IAE Lyon, ex-KPMG]
  Mission: to develop the encapsulation of therapeutic molecules or enzymes into red blood cells in order to improve the therapeutic index, notably in orphan indications or underserved subpopulation of higher risk patients Oper.Dir.:
Clients: Prescribers Sc.Dir.-CSO: Godfrain (Yann) [co-founder, born 1970, Ph.D., Biomedical Eng., ex-BioAlliance Pharma, Hemosystem, Hemoxymed]
www.erytech.com Age: 16 year(s) Pharm.Dir.: Bailly (David) [Pharm.Dr, Chem.Eng. (Montréal), ex-Skyepharma, Aguettant]
Fin.Dir.-CFO:
BusDev: Bouvier (Maud) [Sup de Co (Grenoble)]
Financers (Hist.): AXA P.E., Auriga Partners, AGF P.E., Capdecisif, Créalys, Idinvest
Eye Tech Care 2008 Rhône-Alpes Development, Devices Personal venture | Ophtalmology Trade
Rillieux la Pape (near Lyon) Key words: Ultra-sounds, Ophthalmology, Glaucoma, EYEOP1 Managing Dir.-CEO: Romano (Fabrizio) [co-founder, born 1962, Vet.D., ex-Edap TMS]
  Mission: to develop a proprietary ultrasound-based procedure for treating eye diseases Clin.Dir.: Farcy (Laurent) [co-founder, born 1973, Ms. biochemistry, ex-Medicrea, Sofradim]
Clients: undisclosed Indus.Dir.: Chapuis (Philippe) [co-founder, born 1968, Eng. ESEM Orléans, IAE, ex-Edap TMS]
www.eyetechcare.com Age: 12 year(s) Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Crédit Agricole, CEA Valorisation, SHAM
Flamel Technologies 1990 Rhône-Alpes Delivery, Drugs Start-up | Multiple Trade
Venissieux (also, Design, Devices) Managing Dir.-CEO: Anderson (Michael S.) [ex-Éclat Pharmaceuticals, KV Pharmaceutical, Ther-Rx Corporation, Schein, A.H. Robins Company]
  (near Lyon) Key words: Polymer encapsulation, Interferon, Micropump, Medusa, Drug-protein delivery, Long Action Sc.Dir.-CSO: Meyrueix (Rémi) [Ph.D., Eng. Physics, ex-Rhône Poulenc Santé] & Castan (Catherine) [Ph.D.]
Mission: to improve the therapeutic characteristics, safety profile and ease of use of a wide variety of existing drugs, by using proprietary drug delivery platforms, Medusa for therapeutic proteins and peptides and Micropump for small molecules, with expertise in polymer chemistry Oper.Dir.-COO: Jorda (Raphaël) [Ph.D., Eng. chemistry, ex-Rhône Poulenc Santé]
www.flamel.com Clients: Pharmaceutical industry (own development up to pre-registration), Agrochemical industry Fin.Dir.-CFO: Crouzet (Siân) [ex-McCormik, Ernst & Young]
Age: 30 year(s) BusDev: Lisi (Steven A.) [ex-Deerfield Mgt, Panacea Asset Mgt, Millenium Partners]
Strat.Comm.Dir.: Mosseri Marlio (Charles)
Financers (Hist.): Public (Nasdaq)
Fluofarma 2003 Aquitaine Contract, Research (also, Contract, Services) Spin-off | Multiple Subcontractor
Bordeaux Key words: High Content Screening (HCS), Automated flow cytometry, Cell-based assays Managing Dir.-CEO: Pin (Jean-Baptiste) [founder, born 1974, ex-Ernst & Young Biotechnology]
  Mission: to provide third parties with High Content Screening (in-cellulo screening) services for target and drug discovery, predictive toxicity testing and cosmetics development Sc.Dir.-CSO: Ichas (François) [Ph.D. biomedical sciences, ex-Inserm]
Clients: Pharmaceutical industry, Biotech, Cosmetic industry Sales&Mktg.Dir.: Plane (Julie) [ex-Avenium Consulting]
www.fluofarma.com Age: 17 year(s) Fin.Dir.-CFO:
BusDev: Brisson (Bruno) [ex-Cellectis, Mauna Kea Technologies, Biospace Lab]
Financers (Hist.): privately owned (registered capital 2006 = 0.24 M€)
GemacBio 1999 Aquitaine Development, Diagnostics Personal venture | CNS Trade
Berganton, Saint Jean d’Illac (also, Contract, Manufacturing) Managing Dir.-CEO: Lurton (Louis) [born 1956]
  (near Bordeaux) Key words: Antibodies, Customization, CNS disorders, Auto-immune diseases Sc.Dir.-CSO:
Mission: to develop a wide range of monoclonal and polyclonal antibodies against neurotransmitters, nitrosylated and nitrated amino-acids, bacterial antigens Fin.Dir.-CFO:
www.gemacbio.com Clients: Distributors, Pharmaceutical industry, Biotech, Research labs BusDev:
Age: 21 year(s) Financers (Hist.): IRDI, ACI, SOCRI, Oséo/Anvar, business angels
Note: the company website has ceased to provide with news since Fall 2009
Genepep 2003 Midi-Pyrénées Contract, Research Personal venture | Multiple Preclin
St Jean de Védas (also, Discovery, Drugs) Managing Dir.-CEO: Puget (Karine) [co-founder, born 1970, Ph.D., ex-CNRS]
  (near Montpellier) Key words: Peptides, Transcriptomes, Bio-informatics softwares Sc.Dir.-CSO: Puget (Karine)
Mission: to provide third parties with custom peptide synthesis, antibody production, peptide and protein sequencing, mass spectrometry, and to design own peptides for therapeutic research Fin.Dir.-CFO: Chorro (Karine) [HEC (1994), also Deputy CEO]
www.genepep.com Clients: Pharmaceutical industry (own development up to proof of concept) BusDev:
Age: 17 year(s) Financers (Hist.): Sud Angels
Genewave 2001 IDF Design, Devices Personal venture | Multiple Trade
Paris Key words: Automated real-time micro-array, Hybridization imaging systems, Low-cost micro-array readers, HybLive President: Desforges (François-Xavier) [born 1960, Ph.D. Electronics, ex-Photonetics]
  Mission: to develop, manufacture and market cutting-edge microarray instrumentation for diagnostic, clinical and life science research Managing Dir.-CEO: Choumane (Houtaï) [Ph.D. Optics, also co-CEO]
Clients: Research labs, Biotech, Other Institutions, OEM markets Sc.Dir.-CSO: Weisbuch (Claude) [co-founder, born 1945, Ph.D. physics, Normale Sup, CNRS, University Professor (USA), ex-Bell Laboratories, Saint-Gobain, Thomson-CSF]
www.genewave.com Age: 19 year(s) Tech.Dir.-CTO: Rattier (Maxime) [Ph.D., Polytechnique, ex-Luxtera]
Dev.Dir.: Marcy (Yann) [Ph.D., biological physics (Institut Curie)]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.):
Note: no legal accounting report since 2006, website contents much reduced in October 2012 (e.g. no more news)
Genfit 1999 North-Picardie Discovery, Drugs Start-up | Cardiovasc Clinical
Lille Key words: Cardiometabolic diseases, Dyslipidemia, Diabetes Managing Dir.-CEO: Mouney (Jean-François) [co-founder, born 1955, Sup de Co (Paris), ex-M&M, also chairman]
  Mission: to bring therapeutic and diagnostic solutions to combat the major health concerns of diabetes, its associated risk factors, and its complications Oper.Dir.-COO: Darteil (Raphaël) [Ph.D. molecular and cellular biology, ex-Aventis]
Clients: Pharmaceutical industry Sc.Dir.-CSO:
www.genfit.com Age: 21 year(s) Fin.Dir.-CFO: Huitorel (Nathalie) [Sup de Co (Lille), ex-MS Composites, Finuchem]
BusDev:
Financers (Hist.): Finorpa, Nord Cration, BP Création, Ya Global, University Lille II, Public
Genomic Vision 2004 IDF Discovery, Drugs Personal venture | Multiple Launch
Paris (also, Discovery, Diagnostics) Managing Dir.-CEO: Bensimon (Aaron) [born 1957, co-founder, Ph.D. molecular biology, ex-Institut Pasteur]
  Key words: Diagnostics, Nanotechnology, DNA, Molecular combing Sc.Dir.-CSO: Conseiller (Emmanuel) [Ph.D., ex-Sanofi-Aventis, Rhône-Poulenc Rorer]
Mission: to develop novel diagnostic, biomarkers and drug discovery solutions based on proprietary nanotechnology for DNA analysis in the areas of cancer and acute diseases Oper.Dir.-COO: Nerson (Daniel) [born 1958, co-founder, Ph.D., ex-Pasteur Mediavita, Dade-Behring]
www.genomicvision.com Clients: Pharmaceutical industry (Sanofi-Aventis), Biotechs Fin.Dir.-CFO: Martin (Erwan) [ex-Cytomics (co-founder), Syndex, Université de Marne la Vallée (Professeur, finances)]
Age: 16 year(s) BusDev: Abut (Fadilha)
Financers (Hist.): Société Générale Asset Management Alternative Investments (SGAM AI), Vesalius BioCapital
GenoSafe 2003 IDF Contract, Services Start-up | Multiple Subcontractor
Évry Key words: Bio-therapeutics, Drug evaluation Managing Dir.-CEO: Roques (Stéphane) [born 1972, SupdeCo, ex-Arthur Andersen, AFM, Genethon]
  (near Paris) Mission: to evaluate the efficacy and safety of biotherapeutic products (viral and non-viral vectors, vaccines, recombinant proteins, monoclonal antibodies, cellular products …), for third parties Sc.Dir.-CSO: Audit (Muriel) [Ph.D. Biology, ex-Genethon]
Clients: Pharmaceutical industry, Biotechs, Research labs Fin.Dir.-CFO:
www.genosafe.com Age: 17 year(s) BusDev: Zuliani (Vincent) [Ms. microbiology, ex-Genethon]
Financers (Hist.): A2I (seed), Genethon, AFM
GenoScience Pharma 2001 Méditerranée Discovery, Drugs Personal venture | Virus Preclin
Marseille (also, Contract, Research) Managing Dir.-CEO: (interim) Halfon (Philippe) [founder, born 1960, M.D., Ph.D., Alphabio (CEO)]
  Key words: Antivirals, Protease inhibitor, HCV Sc.Dir.-CSO: Benech (Philippe) [Ph.D., ex-CNRS, founder Genesodi]
Mission: to discover, develop and commercialize novel antiviral products (combining internal expertise in viral infections and unique molecular modeling through GenMol proprietary software (current focus on compounds for the treatment of hepatitis C infections) Tech.Dir.-CTO: Pépé (Gérard) [Ph.D., Research Director (CNRS)]
www.3dgenoscience.com Clients: undisclosed Fin.Dir.-CFO: Corroy (Jean-Paul) [Sup de Co, ex-Alphabio]
Age: 19 year(s) BusDev:
Financers (Hist.):
Notes : no news on website since 2005 and URL changed from genosciencepharma.com back to old 3dgenoscience.com in 2011 ; legal data show a loss in capital in July 2011 (recurrent)
Genoscreen 2001 North-Picardie Contract, Research Spin-off | Genome Subcontractor
Lille Key words: DNA, Genome, Sequencing, Genotyping, Mutation detection, Gene expression, Microbial identification, Microbial typing Managing Dir.-CEO: Tordeux (André) [born 1947]
  Mission: to develop and to realize innovative services on all kind of genomes to provide answers that best suit the needs of research laboratories, by using own high throughput equipments Sc.Dir.-CSO: Tordeux (André), also Ferreira (Stéphanie) [Ph.D.]
Clients: Pharmaceutical industry, Research labs, Life science industries, Academic research institutions Sales Dir.: Antigny (Frédéric) [M.Sc., MBA]
www.genoscreen.fr Age: 20 year(s) Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned
GenOway 1999 Rhône-Alpes Contract, Research Spin-off | Genome Subcontractor
Lyon Key words: Gene amplification, Clonal animal, Mouse, Toxicology tests Managing Dir.-CEO: Fraichard (Alexandre) [co-founder, born 1968, Ph.D. molecular biology (1997), Normale Sup (Lyon), MBA (HEC)]
  Mission: to provide third parties with customized and ready-to-use genetically modified mouse and rat models (Knock-out, conditional Knock-out, Knock-in, RNAi, humanized, transgenic mice and rats) Sc.Dir.-CSO:
Clients: Research labs Fin.Dir.-CFO: de Poncins (Gilles) [co-founder, Science Po (Paris), MBA, ex-Renault, Qualis, Sofecome]
www.genoway.com Age: 21 year(s) BusDev: Thiam (Kader)
Financers (Hist.): Dassault Développement, CDC E.I., Finoway (Qualis), Rhône Alpes Création, Public
Genticel 2001 Midi-Pyrénées Discovery, Immunology Spin-off | Vaccines Clinical
Labège Key words: Therapeutic vaccines, HPV, Cancer, Viral and bacterial infections, ProCervix Managing Dir.-CEO: Timmerman (Ben) [founder, born 1959, Ph.D. Molecular Genetics, MBA, ex-Novartis Agro, Procordia]
  (near Toulouse) Mission: to develop immuno-therapeutic products for the treatment of infection, neoplasia and cervical cancer, caused by Human Papillomavirus (HPV) Sc.Dir.-CSO: Bissery (Marie-Christine) [Ph.D., Pharm.D., ex-Sanofi–Aventis, Rhône-Poulenc]
Clients: Prescribers Fin.Dir.-CFO: Koch (Martin) [Eng., MBA, ex-Eli Lilly, Cap Gemini, Elan, Zeneus, Cephalon]
www.genticel.com Age: 19 year(s) BusDev:
Financers (Hist.): Institut Pasteur, FAM-Midi-Pyrénées, Edmond de Rothschild Investment Partners, IRDI, Amundi Private Equity Funds, InnoBio, FSI
Note : from inception to February 2010, the company name has been BT Pharma (BT for Benedikt Timmerman, Founder)
GTP Technology 2000 Midi-Pyrénées Contract, Manufacturing Spin-off | Multiple Subcontractor
Labège (also, Design, Drugs) Managing Dir.-CEO: Pease (Christopher) [born 1963, M.Sc. Insa (Lyon), ex-Millipore], also Managing dir. Darlington Life Science
  (near Toulouse) Key words: In-vitro protein production, Gene work, Eiffel biostructure, L-lactis, Sensorines, Therapeutic protein, Cancers Sc.Dir.-CSO: Ginisty (Hervé) [born 1971, Ph.D. molecular biology]
Mission: to provide third parties with taylor-made solutions for the engineering and expression of recombinant proteins, and, to undertake own research on the L.lactis system for therapeutic proteins production Oper.Dir.-COO: Devic (Éric) [founder, born 1966, Pharm.D., Ph.D. molecular biology], also chairman
www.gtptech.com Clients: Pharma industry, Biotechs, Research labs Tech.Dir.-CTO: Mozo (Julien) [Ph.D.]
Age: 20 year(s) Fin.Dir.-CFO:
BusDev: Hountondji (Séverine) [M.Sc. Insa]
Financers (Hist.): privately owned, undisclosed
Helios Biosciences 2002 IDF Discovery, Targets (also, Contract, Research) Academic | Cancers Preclin
Romainville Key words: Tissue expression, InSitu Hybridization, Biomarkers, Prostate cancer, Epilepsy, SIMPathway Managing Dir.-CEO: Dumas (Jean-Baptiste) [founder, born 1958, Ph.D., ex-Genset, Genethon]
  (near Paris) Mission: to research for own pipeline or to provide third parties with proprietary tools in the identification and characterization of therapeutic targets and biomarkers Sc.Dir.-CSO: Dumas (Sylvie) [Ph.D., Normale Sup, ex-CNRS]
Clients: Research labs, Cosmetic and Pharma industries Fin.Dir.-CFO:
www.helios-bioscience.com Age: 18 year(s) Med.Dir.-CMO: Vujasinovic (Todor) [M.D., ex-CNRS]
Financers (Hist.): privately owned (registered capital 2006 = 0.15 M€)
Notes: no legal accounting report since 2006 ; the company is facing legal redress since September 12. 2012 ; URL has changed in 2012 from www.helios-biosciences.com to www.helios-bioscience.com (without ‘s’)
Hemarina 2007 Bretagne Discovery, Drugs Spin-off | Blood Preclin
Morlaix Key words: Hemoglobin, Blood-transfers, Transfusion, Sea-Invertebrate, Arenicole Managing Dir.-CEO: Zal (Franck) [co-founder, born 1966, Ph.D. oceanography, ex-CNRS]
  Mission: to develop a new generation of oxygen-carrier for therapeutical and industrial applications (to help cope with the huge deficit of blood worldwide), based on extraction and purification from a marine organism Sc.Dir.-CSO: Zal (Franck)
Clients: Pharmaceutical industry (developement limited to early stage), Biotechs Techn.Dir.-CTO: Rousselot (Morgane), [co-founder, Ph.D., Eng. ENSCMu, ex-GSK]
www.hemarina.com Age: 13 year(s) Pharm.Dir.: Naccache (Alain) [Pharm.Dr]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately-owned, Inserm Transfert Initiative, Synergie Finance, Vaneau, and various business angels (registered capital 2007 = 0.26 M€)
Hybrigenics 1998 IDF Discovery, Drugs Academic | Cancers Preclin
Paris (also, Services, Research) Managing Dir.-CEO: Delansorne (Rémi) [born 1959, Vet.D., Ph.D., ex-Theramex (Merck KgAa)]
  Key words: Protein-protein interaction, Cancer, Inecalcitol, D-vitamin, Protease inhibitor, Protein-interactions maps (PIMs), Ubiquitin Oper.Dir.-COO: Formstecher (Etienne) [Polytechnique, Ph.D., also deputy CEO]
Mission: to develop internal R&D programs on innovative target and therapeutics against cancer and to market proprietary high throughput technology and bioinformatics platforms focused on identification, validation and inhibition of protein interactions Tech.Dir.: Rain (Jean-Christophe) [Ph.D. Molecular Genetics, co-founder, also deputy CEO]
www.hybrigenics-services.com Clients: Prescribers I.T.Dir.-CIO: Collura (Vincent) [Ph.D. structural bioinformatics]
Age: 23 year(s) Financers (Hist.): Medicis, Rendex, Sofindev, IMH, Lombard Odier, Alafi Capital, Life Science Partners, Banexi V.P., C.F. Edmond de Rothschild, Public
note : in September 2012, the company changes its URL from www.hybrigenics.com to www.hybrigenics-services.com
Hyphen BioMed 1999 IDF Design, Diagnostics Personal venture | Cardiovasc Trade
Neuville-sur-Oise (also, Discovery, Diagnostics) Managing Dir.-CEO: Amiral (Jean) [born 1952, Ph.D., Immunologist, Biochemist, ex-Serbio Stago (CSO)]
  (near Paris) Key words: Research reagents, Thrombosis, Haemostasis, Auto-Immunity, Zymutest Sc.Dir.-CSO: Vissac (Anne Marie) [born 1956, ex-Project Leader Serbio Stago]
Mission: to develop a full line of innovative kits in diagnostic and research reagents and biochemicals, manual or automated, designed with clotting, chromogenic or immunological methods, for the exploration of Thrombosis, Haemostasis, Fibrinolysis and Auto-Immunity Fin.Dir.-CFO:
www.hyphen-biomed.com Clients: Research labs, Pharmaceutical industry BusDev (& sales): Penissard (Véronique)
Age: 21 year(s) Financers (Hist.): privately owned, IDF Développement, Banque Populaire
Imagene 1998 Aquitaine Contract, Manufacturing Personal venture | Genome Trade
Pessac Key words: DNA-conservation, Encapsulation, Extraction Managing Dir.-CEO: Tuffet (Sophie) [founder, Ph.D. biology]
  (near Bordeaux) Mission: to provide third parties with high quality, long term preservation of DNA at room temperature for large scale genomic resources banks Sc.Dir.-CSO:
Clients: Research labs Fin.Dir.-CFO:
www.imagene.fr Age: 22 year(s) BusDev:
Financers (Hist.): OTC A.M. and Aquitaine Création Investissement
ImmunId 2005 Rhône-Alpes Contract, Research Personal venture | Multiple Trade
Grenoble Key words: Personalized diagnostics, Combinatorial Repertoire analysis, Immunology analysis, Immunodeficiency, Immuno-monitoring, T & B cell repertoire, Genomic DNA, Infectious diseases, Auto-immune diseases, Blood cancers, Lymphoma and Leukemia diagnosis, ImmunTracker, ImmunIg Managing Dir.-CEO: Pasqual (Nicolas) [co-founder, born 1977, Ph.D. molecular biology, ex-CEA]
  Mission: to provide third parties with innovative diagnostic and prognostic tools and high value-added services to decrease clinical study costs by selecting better immuno-drug candidates and by measuring immuno-reconstitution and suppression kinetics Sc.Dir.-CSO: Pasqual (Nicolas)
Clients: Research labs, Hospitals, Pharmaceutical industry Oper.Dir.-COO: Weisbuch (Sébastien) [born 1977, Ph.D. nanobiology, ex-CEA]
www.immunid.com Age: 15 year(s) Tech.Dir.-CTO: Mouret (Jean-François) [Pharm.D., ex-Applied Biosystems, Cogenics, Genome Express (co-founder)]
Fin.Dir.-CFO:
BusDev: Plantier (Nadia)
Financers (Hist.): privately owned (registered capital 2006 = 0.053 M€)
Note : website revamped in March 2009
Immutep 2001 IDF Discovery, Immunology Spin-off | Cancers Clinical
Orsay (also, Discovery, Diagnostics) Managing Dir.-CEO: Hawken (John B.) [co-founder, born 1948, Ms. chemistry (Oxford), MBA, ex-Diatos, EntoMed, Neurotech, Aptanomics, Shell]
  (near Paris) Key words: Cancer, Chronic Infectious Diseases, T Cell Immune responses, Immuno-therapy, MABs, Vaccines, Lag-3 protein Sc.Dir.-CSO: Triebel (Frédéric) [co-founder, born 1954, M.D., Ph.D. immunology, ex-Inserm, Prof. Immunology, Paris University, Institut Gustave Roussy (IGR)]
Mission: to develop immunostimulatory factors for the treatment of cancer and chronic infectious diseases and immunomodulatory therapeutic antibodies for the treatment of cancers or autoimmune diseases Fin.Dir.-CFO:
www.immutep.com Clients: Prescribers BusDev:
Age: 19 year(s) Financers (Hist.): Innoven Partenaires, H2I
Imstar 1985 IDF Contract, Services Spin-off | Studies Subcontractor
Paris Key words: Microscopic imaging, Cell screening, Systems, Instruments, High throughput, Pathfinder Managing Dir.-CEO: Soussaline (Françoise) [born 1945]
  Mission: to provide third parties with complete vertical solutions for fully automated high-throughput cellular analysis, in the fields of genotoxicity and environmental toxicity, focused on compound screening, biomonitoring, cytopathology, and dedicated to research, diagnostic, staging and drug discovery Sc.Dir.-CSO: Soussaline (Françoise)
Clients: Research labs Fin.Dir.-CFO:
www.imstar.fr Age: 35 year(s) BusDev:
Financers (Hist.): privately owned
In-Cell-Art 2005 Bretagne Design, Delivery Personal venture | Multiple Preclin
Nantes (also Discovery, Drugs) Managing Dir.-CEO: Peyrot (Alain) [ex-Pharmacia, Sanofi, Mérieux, Wellcome, Wyeth]
  Key words: Supramolecular nanocarriers, Intracellular delivery, Polypeptide deficiencies, siRNA therapeutics, DNA vaccines, Antibodies production, In vitro transfection Sc.Dir.-CSO: Pitard (Bruno) [co-founder, Ph.D., ex-Aventis Pasteur, Rhône Poulenc Rorer, CNRS, Inserm]
Mission: to ascertain the delivery of a drug to the heart of the cell, the prolongation of its bioavailability, the vectorisation of DNA or RNA-based active principles Oper.Dir.-COO: Belloc (Chloé) [born 1977, Ph.D., MBA]
www.incellart.com Clients: Pharmaceutical industry, Biotechs, Academic labs Fin.Dir.-CFO:
Age: 15 year(s) BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.05 M€)
Indicia Biotechnology 1998 Rhône-Alpes Contract, Research Personal venture | Studies Subcontractor
Lyon Key words: Microparticle technology, Immunoassay, Reagents, Luminex, OEM dosing methods, OEM production services Managing Dir.-CEO: Legastelois (Stéphane) [born 1960, Ph.D. biochemistry, ex-Merck KgAa, Indicia Diagnostics]
  Mission: to provide third parties with solutions in R&D and manufacturing by providing a complete range of comprehensive services in the areas of immuno-diagnostics, microbiology and sterile reagents Oper.Dir.-COO: Panier (Elodie) [Ms.Sc., Eng. IUP, DESS Management]
Clients: Pharmaceutical industry, Diagnostics industry Fin.Dir.-CFO:
www.indicia.fr Age: 22 year(s) BusDev:
Financers (Hist.): privately owned (registered capital 2010 = 0.51 M€)
Note : initial company registering under Indicia: 1984.03
InGen Biosciences 2001 IDF Design, Diagnostics Start-up | Infections Trade
Chilly-Mazarin Key words: Serology, In-vitro, Biomarkers, Infectious diseases, Bacterial antigens, Microbiology, Non-invasive testing, Capucine, Abag Managing Dir.-CEO: Buckle (Isabelle) [Ph.D. microbiology, ex-Applied Biosystems, Ciphergen Biosystems, Amersham Pharmacia Biotech]
  (near Paris) Mission: to design and manufacture protein biomarkers for multiparametric diagnostic in infectious diseases Sc.Dir.-CSO: Mignon Godefroy (Karine) [Ph.D, ex-Chemunex, BMD, Bio-Rad]
Clients: Pharmaceutical industry Oper.Dir.-COO: Mollet (Patrick) [ex-Organon]
www.ingen.fr Age: 19 year(s) Mktg.Dir.: Martin (Jacques) [Eng. ESITPA, ex-Clonatec]
Fin.Dir.-CFO: Elorga (Esteban) [Sup-de-Co, ex-Arhur Andersen]
BusDev:
Financers (Hist.): Innoven Partners, Société Générale A.M.
Notes : Ingen website, acquired in 2006, updated with Ingen Biosciences (no company website ever as Abag) ; the company is subject of a take over in Novemebr 2012
Innate Pharma 1999 Méditerranée Discovery, Drugs Start-up | Cancers Clinical
Marseille Key words: Immuno-therapy, Immuno-modulators, Toll-like receptors (TLR), Cancer, IPH 4201 Managing Dir.-CEO: Brailly (Hervé) [co-founder, born 1961, Ph.D., ex-Immunotech-Beckman-Coulter]
  Mission: to develop first in class drugs targeting the innate immune system Sc.Dir.-CSO: Romagné (François) [Ph.D., co-founder, ex-Immunotech-Beckman-Coulter]
Clients: Prescribers Clin.Dir.-CMO: Rozencweig (Marcel) [M.D., ex-BMS]
www.innate-pharma.com Age: 21 year(s) Fin.Dir.-CFO: Moukheibir (Catherine) [MBA, ex-Zeltia, Shire, Movetis]
BusDev: Morel (Yannis) [Ph.D. oncology, NormalSup]
Financers (Hist.): Sofinnova Partners, Auriga Partners, GIMV, Alta Partners, Gilde Biotech & Nutrition, Pechel Industries, Innoveris, Quilvest, NIF Ventures, Novo-Nordisk, Public
InnaVirVax 2008 IDF Discovery, Immunology Start-up | HIV Clinical
Évry (also, Discovery, Diagnostics) Managing Dir.-CEO: Crouzet (Joël) [born 1958, Ph.D., Eng. Agro (Grignon), ex-Eurobiobiz, Inserm Transfert, Neurotech, APCells, Rhône-Poulenc Rorer]
  (near Paris) Key words: HIV, CD4 restoration, Predictive test Sc.Dir.-CSO: Crouzet (Joël)
Mission: to develop a new HIV therapeutic vaccine aiming to restore CD4 to normal levels (without immunodeficiency) and to design a diagnostics test able to predict the evolution of the AIDS pathology of a given patient Fin.Dir.-CFO:
www.innavirvax.fr Clients: Pharmaceutical industry Proj.Mgr.: Ho Tsong Fang (Raphaël) [Vet.D., Ph.D. microbiology and medical virology, ex-Institut Pasteur, UCLA (Los Angeles)]
Age: 12 year(s) Financers (Hist.): Pradeyrol Développement, Fa Dièse, CapDecisif Management, Genopole 1er Jour
Innovative Health Diagnostics 2009 Alsace Discovery, Diagnostics (also, Contract, Research) Personal venture | Alzheimer, Preclin
Strasbourg Key words: Alzheimer, Biomarkers, DiagAlz Managing Dir.-CEO: Regnaut (Xavier) [co-founder, born 1964, Eng. Agro, Ms. Genetics, EMBA HEC]
  Mission: to develop and sell diagnostic solutions in the field of neurodegenerative diseases, based on detection of specific biological blood markers Sc.Dir.-CSO: de Barry (Jean) [co-founder, Ph.D., Eng. Chemistry, ex-Inserm)
Clients: Prescribers, Hospitals Clin.Dir.-CMO: Sellal (François) [co-founder, M.D., Pharm.D., ex-CM2R]
www.ihdiag.com Age: 11 year(s) Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2009 = 0.05 M€), Oseo, FEDER, Sodiv Alsace
Note : IHD is the trade mark company name
IntegraGen 2000 IDF Discovery, Diagnostics Spin-off | Cardiovasc Launch
Évry Key words: Genes, Genomic mutations, Diabetes, Obesity, Bipolar disorders, Schizophrenia, Autism, GenomeHIP Managing Dir.-CEO: Courtieu (Bernard) [born 1964, Vet.D., MBA, ex-Gemini Conseil, Ariba]
  (near Paris) Mission: to research in gene targets and to market molecular diagnostics products and services that provide clinicians with new tools of personalized diagnosis, treatment, and therapy Sc.Dir.-CSO: Liebaert (François) [MBA, ex-Schering, Abbott]
Clients: Prescribers Fin.Dir.-CFO: Riot-Lamotte (Laurence) [CESEM, ex-Aureus-Pharma, Deloitte & Touche, Thomson, Deutsche Telekom France]
www.integragen.com Age: 20 year(s) SalesMktg: Martin (Emmanuel) [Pharm.D., ex-Applied Biosystems]
BusDev: Brady (David) [MBA, ex-Biogen-Idec, Lonza]
Financers (Hist.): CDC Innovation, GenAvent, Bioam, Bay Tech, AGF P.E., Société Générale A.M., DSM
Ipsogen 1999 Méditerranée Discovery, Diagnostics Personal venture | Cancers Trade
Marseille Key words: Assays, Molecular expression, Biomarker, Blood cancer, Leukemia Managing Dir.-CEO: Fert (Vincent) [co-founder, born 1959, Ms. immunology, ex-Immunotech, Beckman Coulter]
  Mission: to design, manufacture and market molecular assays with proven expertise in identifying and translating key discoveries into essential tests intented to support personalized approach to cancer treatment Sc.Dir.-CSO: Hermitte (Fabienne) [co-founder, Ph.D., INA, ex-Rhône Poulenc, CNRS]
Clients: Research labs, Prescribers Oper.Dir.-COO: Debono (Stéphane) [born 1975, ESIM, ex-Immunotech, Beckman Coulter]
www.ipsogen.com Age: 21 year(s) Med.Dir.-CMO: Peyro-Saint-Paul (Hélène) [M.D. (Neurology), MBA (Essec), ex-B.M.S., Actelion, Serono]
Fin.Dir.-CFO: Boissel (Pascale) [HEC, ex-Price Waterhouse Coopers, Danone, Lafarge]
SalesMktg: Danan (Corinne) [ISC, MBA (Insead, 1990), ex-Monogram Biosciences, Eli Lilly]
BusDev:
Financers (Hist.): Samenar (Caisse d’Epargne), Institut Paoli-Calmettes, Société Générale A.M., Matignon Technologies, Innovéris, Connecticut Innovations, Viveris, Natixis, Octalia, Public
Note : trade mark logo : «Ipsogen, cancer profiler»
I-Stem 2004 IDF Discovery, Drugs Start-up | Multiple Incub
Évry (also, Contract, Research) Managing Dir.-CEO: Peschanski (Marc)
  (near Paris) Key words: Stem cells, Monogenic diseases, Drug Discovery, Cell therapy, Pathological modelling, HTS & HCS Sc.Dir.-CSO: Peschanski (Marc)
Mission: to develop new treatments based on the potential offered by pluripotent stem cells (human embryonic cells and iPS) and applicable to rare diseases of genetic origin Fin.Dir.-CFO: Zakhia (Raymond)
www.istem.eu Clients: undisclosed BusDev: Duprat (Sébastien) [born 1975, D.E.A. Biology, ex-ESTOOLS, Scientific Research Helsinki-Lille]
Age: 16 year(s) Financers (Hist.): INSERM, AFM (French Muscular Dystrophy Association)
Note : a public-private Institute equally funded by INSERM and AFM, on a yearly budget (about 7 M€ each year between 2005 and 2008)
Karcinolys 2005 Rhône-Alpes Development, Drugs Start-up | Cancers Incub
Lyon Key words: Biologicals, Liver cancer, Pancreatic cancer, Herpes virus Managing Dir.-CEO: Béjot (Jean-Luc) [born 1957, M.D., ex-OPI, Novartis, Quintiles, Genzyme, Ipsen, Cassenne]
  Mission: to develop a new generation of tumour-selective «replication conditional» HSV-1 derived oncolytic viruses Sc.Dir.-CSO:
Clients: Pharmaceutical industry Fin.Dir.-CFO:
www.no-website.net Age: 15 year(s) BusDev:
Financers (Hist.): privately owned (registered capital 2009 = 0.1 M€)
Communication : no website, yet
Keosys 2001 Bretagne Development, Devices Start-up | Cancers Trade
Saint Herblay (near Nantes) Key words: Nuclear medicine, Digital imaging, Radiology, Mammography, I.T. programmes, Visio+, Positoscope Managing Dir.-CEO: Fortineau (Jérôme) [born 1968, co-founder, Eng., ex-Alcatel]
  Mission: to develop new imaging and communication systems for nuclear medicine and radiology Sc.Dir.-CSO: Terve (Pierre)
Clients: Distributors or directly to Hospitals, Clinics, Cancer centers, Radiologists Fin.Dir.-CFO:
www.keosys.com Age: 20 year(s) BusDev:
Financers (Hist.): Lumiplan, Vizille Capital Innovation (CIC group), Pays de Loire Développement, Sodera
Note: no legal accounting report since 2007
MABlife 2000 IDF Discovery, Drugs Personal venture | Cancers Clinical
Évry Key words: MABs, Antibody-based therapeutics, Cancer, Immuno-therapy, Angiogenesis Managing Dir.-CEO: Vallet (François) [born 1958, Polytechnique, Ph.D. physics, ex-Genewave (co-founder)]
  (near Paris) Mission: to develop proprietary antibody-based therapeutics for the treatment of cancer Sc.Dir.-CSO: Boumsell (Laurence)
Clients: Pharmaceutical industry (own development up to phase II included) Fin.Dir.-CFO: vacant
http://www.mablife.com Age: 20 year(s) BusDev: vacant
Financers (Hist.): Génopole 1er Jour, IxCore, Anvar
Notes : full company legal name is Monoclonal Antibodies Therapeutics, up to 2011 ; previous URL was www.matbiopharma.fr ;
Magnisense 2003 IDF Discovery, Diagnostics Start-up | Point of Care Testing Trade
Rosny-sous-Bois (near Paris) Key words: Magnetic immunoassays, In-vitro diagnostics, Point-of-Care, Rapid tests, Super-paramagnetic particles, Magnetic detection, Portable reader, Cardiac markers, Infections, MIAtek, MIAstrip, MIAflo Managing Dir.-CEO: Lenglet (Luc) [born 1964, Ph.D., Normale Sup (Paris), ex-Rhodia, Arthur D. Little]
  Mission: to develop and market next-generation magnetic immunoassays that improve rapid diagnostic performance for human and animal diagnostics, food safety and environmental protection testing (immunoassays that are based on magnetic bead markers, which can be used to achieve the accuracy of laboratory testing with the ease of use of rapid test methods) Sc.Dir.-CSO: Nikitin (Petr) [Ph.D.]
Clients: Diagnostic industry Fin.Dir.-CFO:
www.magnisense.com Age: 17 year(s) RegMktg: El Yousfi (Hayat) [Mme, Pharm.D.]
BusDev: Péquignot (Clayton) [Ms. Biotechnology, ex-Cap Gemini Ernst and Young, Venstrata]
Financers (Hist.): Baring Vostok Capital Partners, Psilos Group, Seventure, Creadev (registered capital 2007 = 0.1 M€)
Note : legal foundation, February 20. 2007 (not 2003, as per company)
Mapreg 2000 IDF Discovery, Drugs Academic | CNS Clinical
Le Kremlin-Bicêtre Key words: Microtubules, CNS diseases, Spinal cord injury, Traumatic brain injury, Neurosteroids Managing Dir.-CEO: Baulieu (Etienne Emile) [born 1926, M.D., Ph.D.]
  (near Paris) Mission: to dscover new drugs based on a novel mechanism for the protection and repair of nerve connections Managing Dir.-CEO (co-): Villey (Isabelle) [Ph.D., MBA, ex-Vision Institute]
Clients: Pharmaceutical industry (own development up to phase II included) Sc.Dir.-CSO: Robel (Paul) [M.D.]
www.mapreg.com Age: 20 year(s) Oper.Dir.-COO: Baeuerle (Ralf) [PhD]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.):
Note: according to the company (November 2012, but website not regularly updated), total raised capital is close to 5 M€.
Mauna Kea Technologies 2000 IDF Discovery, Diagnostics Personal venture | Multiple Trade
Paris Key words: Fluorescence, Fiber optic, Microscopy, Pneumology, Gastrology, CellVizio Managing Dir.-CEO: Loiseau (Sacha Alexandre) [co-founder, born 1970, Ph.D., Eng. École Polytechnique, ex-CNES]
  Mission: to develop in vivo cellular imaging systems for biomedical and medical applications Sc.Dir.-CSO: Lacombe (François) [Ph.D. astrophysics, Normale Sup]
Clients: Specialist doctors Fin.Dir.-CFO: Cohen (Éric) [MBA, ex-Biocortech, Hybrigenics, Teva, Radio BFM]
www.maunakeatech.com Age: 20 year(s) BusDev:
Financers (Hist.): Psilos Group, Seventure, CreAdev
Medesis Pharma 2003 Langeudoc-Roussillon Discovery, Drugs Personal venture | Multiple Clinical
Baillargues Key words: Nanotechnology drug delivery systems, Metals low doses, Vanadium, Manganese, Strontium, Metabolic syndrome, Diabetes, Huntington Disease, Bipolar Disorders Managing Dir.-CEO: Maurel (Jean-Claude) [founder, born 1946, M.D., M.Sc., ex-Natura Medica (founder)]
  (near Montpellier) Mission: to develop new innovative treatments of diabetes and neurodegenerative disorders based on metallic ions technology and delivery of nucleic acid (siRNA antisens) Sc.Dir.-CSO: Maurel (Patrick) [Ph.D., ex-Inserm]
Clients: undisclosed Oper.Dir.-COO: Jackson (Peter) [Ph.D.]
www.medesispharma.com Age: 17 year(s) Fin.Dir.-CFO:
BusDev: Jackson (Peter)
Financers (Hist.): privately owned
Mellitech 2005 Rhône-Alpes Discovery, Drugs Spin-off | Cardiovasc Preclin
Grenoble (also, Design, Diagnostics) Managing Dir.-CEO: Platford (Richard) [Ms. mechanical sciences (Cambridge), MBA (LBS), ex-PricewaterhouseCoopers, Cellvir]
  Key words: Type 2 diabetes, Zinc transporter protein Sc.Dir.-CSO: Chimienti (Fabrice) [Ph.D.]
Mission: to develop a new therapeutic and diagnostic approach to type II diabetes based on a proprietary (PCT) zinc transporter protein, only present in insulin-secreting cells Oper.Dir.-COO: Girod-Roux (Pierre-Marie) [also board chairman, DEA (Physiology), Ms. management]
www.mellitech.com Clients: undisclosed Fin.Dir.-CFO:
Age: 15 year(s) BusDev: de Boysson (Yann) [co-founder, Engineer]
Financers (Hist.): privately owned (registered capital 2006 = 0.08 M€)
Metabolys 2008 Rhône-Alpes Contract, Research Spin-off | Testing Proof-of-Concept
Lyon Key words: Metabolomics, Toxicity, Drug candidate Managing Dir.-CEO: Baverel (Gabriel) [born 1947, founder, M.D., University Prof. Lyon]
  Mission: to improve the preclinical evaluation of drug candidates through cellular metabolomics in pharmacology, toxicology and nutrition (identification and quantification of metabolic pathways by the combination of enzymatic and carbon 13 NMR measurements with mathematical models of metabolic pathways) Sc.Dir.-CSO: Baverel (Gabriel)
Clients: Pharmaceutical industry, Research labs Fin.Dir.-CFO:
www.metabolys.org Age: 12 year(s) BusDev:
Financers (Hist.): privately owned (registered capital 2008 = 0.15 M€)
Note: web site, still under construction since inception (May 2011)
MilleGen 1999 Midi-Pyrénées Contract, Manufacturing Personal venture | Multiple Subcontractor
Labège (also, Development, Drugs) Managing Dir.-CEO: Kharrat (Abdel Hakim) [co-founder, born 1961, Ph.D. biology, Ms. Management, ex-EMBL Heidelberg]
  (near Toulouse) Key words: Directed Molecular Evolution (DME), MutaGen, Mutascreen, Gene cloning, High throughput screening, Antibodies, Peptides Sc.Dir.-CSO: Bouayadi (Khalil) [co-founder, Ph.D. molecular pharmacology]
Mission: to develop and and genetically engineer new human therapeutic antibodies based on proprietary Directed Molecular Evolution platform, for third parties and for own pipeline (also, to offer custom services including high-throughput DNA sequencing, bioinformatics, gene cloning and vector development services, peptides synthesis and antibodies engineering and production) I.T.Dir.-CIO: Crozet (Fabien) [Ph.D. molecular neurobiology]
www.millegen.com Clients: Pharmaceutical industry, Research labs, Biotechs Fin.Dir.-CFO:
Age: 21 year(s) BusDev: Deflisque (Anne) [Ms. biochemistry, ex-GE Healthcare]
Financers (Hist.): privately owned (registered capital 2006 = 0.07 M€)
Murigenetics 2005 Méditerranée Discovery, Drugs Personal venture | Genome Preclin
Marseille Key words: Genetic diseases, Charcot-Marie-Tooth (CMT), Hereditary neuropathy, Genetic mental disorders Managing Dir.-CEO: Berro (Marine) [born 1980, ESIL]
  Mission: to develop new drugs for the treatment of serious genetic diseases, based on internal production of genetically modified animal models expressing human genes of patients with hereditary peripheral neuropathies, or mental retardation Sc.Dir.-CSO:
Clients: Prescribers Fin.Dir.-CFO:
www.murigenetics.com Age: 15 year(s) BusDev:
Financers (Hist.): grants by Association Française pour le traitement de la Myopathie (AFM, i.e. French Muscular Dystrophy Association), privately owned (registered capital 2006 = 0.04 M€)
Note : on legal accounts, company have only 1 headcount in 2010 ; at the end of 2011, legal accounts mention 2 headcounts, no revenues and major deficits ; in November 2012, the company website is inactive and the URL dropped
NanoBiotix 2003 IDF Design, Drugs Personal venture | Cancers Clinical
Paris Key words: Nanoparticles, Cancer, NanoXray, Nbtxr3 Managing Dir.-CEO: Levy (Laurent) [co-founder, born 1971, Ph.D. physical chemistry, ex-Altran]
  Mission: to develop new cancer treatments based on proprietary NanoXray platform, as an injection of patented X-ray activated nanoparticles Sc.Dir.-CSO:
Clients: Hospitals Oper.Dir.-COO: Boussaha (Kader) [co-founder, born 1973, Eng. ENI, ex-Altran]
www.nanobiotix.com Age: 17 year(s) Med.Dir.: Borghi (Elsa) [M.D., ex-Sanofi-Aventis]
Fin.Dir.-CFO:
BusDev: Mühlenweg (Bernd) [Ph.D. chemistry, Munich, ex-Wilex]
Financers (Hist.): Cap Décisif, Amorçage Rhône Alpes, Matignon Technologies, OTC Asset Management
Note: an IPO is being prepared in Fall 2012
Neorphys 2005 Méditerranée Discovery, Drugs Personal venture | Multiple Preclin
Nîmes Key words: Nausea-free acute pain, Morphine derivatives, Opioids, Analgesics Managing Dir.-CEO: Lahana (Roger) [co-founder, born 1954, ex-Syntem]
  Mission: to develop a new family of opioid analgesic drug candidates with low side effects Sc.Dir.-CSO:
Clients: Pharmaceutical industry (own development up to phase IIb) Oper.Dir.-COO: Larbouret (Karine) [co-founder, ex-Syntem]
www.neorphys.com Age: 15 year(s) Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Soridec, Inserm-Transfert, CEA Valorisation, Fa Diese 2, Seillans, plus independent business angels
Neovacs 1993 IDF Discovery, Immunology Spin-off | Cancers Clinical
Paris Key words: Therapeutic vaccines, Cancer, Inflammatory diseases, Antibodies, Kinoids, Toxoids Managing Dir.-CEO: Fanneau de la Horie (Guy-Charles) [born 1959, Vet.D., MBA, ex-IDM, Biogen (President Europe), Schering-Plough]
  Mission: to develop anti-cytokine and anti-protein viral regulation therapeutic vaccines to treat certain cancers and inflammatory diseases Sc.Dir.-CSO: Grouard-Vogel (Géraldine) [Pharm.D., Ph.D. immunology, ex-Aventis Pasteur, Walter Reed Army Institute]
Clients: Prescribers Pharm.Dir.: Fanget (Bernard) [ex-Flamel, Sanofi Pasteur]
www.neovacs.com Age: 27 year(s) Fin.Dir.-CFO:
BusDev: Whitehead (Piers) [Oxford, ex-VaxGen, Mercer Management Consulting]
Comm.Dir.: Hocdée-Leroy (Florence) [EM Lyon, ex-Rhône-Poulenc, KBC Securities, Grosvenor]
Financers (Hist.): Truffle Ventures, Europe Innovation, Debiopharm, Novartis, OTC Asset Management
note : at the end of December 2010, Novartis shares account for 26.6%
Netris-Pharma 2008 Rhône-Alpes Discovery, Drugs Personal venture | Cancers Proof-of-Concept
Lyon Key words: Breast cancer, Metastasis, Dependence receptors, Targeted Therapy Managing Dir.-CEO: Bernet (Agnès) [co-founder, born 1968, CNRS]
  Mission: to develop therapeutic compounds for the treatment of cancer, in particular of breast cancer and NSC Lung cancer Sc.Dir.-CSO: Bernet (Agnès)
Clients: undisclosed Fin.Dir.-CFO:
www.no-website.net Age: 12 year(s) BusDev:
Financers (Hist.): privately owned (registered capital 2009 = 0.04 M€)
Neuronax 2003 Centre Discovery, Drugs Spin-off | CNS Proof-of-Concept
Saint Beauzire (also Contract, Services) Managing Dir.-CEO: Gobron (Stéphane) [born 1968]
  (near Clermont-Ferrand) Key words: Neural repair, Parkinson disease, Ataxy, NX peptides Sc.Dir.-CSO: Gobron (Stéphane)
Mission: to develop new drugs for neural repair in cases of neuro-traumas and neuro-degenerative disorders Fin.Dir.-CFO:
www.neuronax.com Clients: Pharmaceutical industry (out-licensing after proof-of-concept) BusDev:
Age: 17 year(s) Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€)
NewVectys 2010 IDF Contract, Research Personal venture | Multiple Preclin
Paris Key words: Gene-Transfer, Vectorology, Translational-Research, Gene-Therapy, Transgenic-Models Managing Dir.-CEO: Duboscq (Antoine) [co-founder, born 1968, ex-Procter & Gamble, Boston Consulting Group, WMI]
  Mission: to develop innovative gene transfer technologies and their applications in transgenic large animal models and gene therapy (own research and co-development as subcontractor) Sc.Dir.-CSO: Sarkis (Chamsy) [co-founder, born 1974, Ph.D., ex-CNRS]
Clients: Pharmaceutical industry, Medical devices industry, Biotechs and CROs Fin.Dir.-CFO:
www.newvectys.com Age: 10 year(s) BusDev:
Financers (Hist.): privately owned (registered capital 2011 = 0.25 M€)
NicOx 1996 Méditerranée Delivery, Drugs Start-up | Multiple Pre-reg
Nice Key words: Nitric oxide, Inflammation, Cardio-metabolic, Osteo-arthritis Managing Dir.-CEO: Garufi (Michele) [co-founder, born 1954, Pharm.D., ex-Recordati, Italfarmaco]
  Mission: to develop and market investigational nitric oxide-donating drugs to meet unmet medical needs, based on proprietary nitric oxide-donating technology Sc.Dir.-CSO: Pfister (Pascal) [M.D., Pharm.D., ex-Novartis, Sandoz]
Clients: Prescribers Fin.Dir.-CFO: Castaldi (Eric)
www.nicox.com Age: 24 year(s) BusDev: Spencer (Gavin) [Ph.D. chemistry, ex-Novartis, Boots]
Financers (Hist.): Apax Partners, Sofinnova, European Medical Ventures, Paribas P.I., Health Capital AB, Oppenheimer Funds, QVT Fund, AQR Capital Management, Pfizer Overseas, Baker Brothers Investments, Public, Managers (less than 3% in 2008)
Nokad 2004 IDF Discovery, Targets Personal venture | Studies Trade
Évry Key words: Secreted proteins inactivation, Functional knock-out, Protein vaccination, Mammals Managing Dir.-CEO: Abina (Amine, Mohammed) [co-founder, born 1963, M.D. immunology, Ph.D., ex-AFSSAPS]
  (near Paris) Mission: to develop and market functional inactivation (knock-out) of secreted endogenous proteins in mammals, through direct in vivo induction of a specific immune response against an endogenous target Sc.Dir.-CSO: Erard (François) [Ph.D., University Professor, ex-Novartis]
Clients: Pharmaceutical industry, Research labs Fin.Dir.-CFO:
www.nokad-technology.com Age: 17 year(s) BusDev:
Financers (Hist.): Cap Décisif and Genopole 1er Jour, SHAM (Société Hospitalière d’Assurances Mutuelles), privately owned
Nosopharm 2009 Méditerranée Discovery, Drugs Personal venture | Infections Proof-of-Concept
Nîmes Key words: Anti-infectives, Clostridium difficile, Multi-resistant Gram-negative pathogens Managing Dir.-CEO: Villain-Guillot (Philippe) [co-founder, born 1977]
  Mission: to discover and develop novel antibiotics against nosocomial and emerging infections Sc.Dir.-CSO: Gualtieri (Maxime) [co-founder, ex-CNRS]
Clients: Biotechs, Pharmaceutical industry (own development up to phase I) Fin.Dir.-CFO:
www.nosopharm.com Age: 11 year(s) BusDev:
Financers (Hist.): privately owned (registered capital 2009 = 0.02 M€)
NovAliX 2002 Alsace Discovery, Drugs Spin-off | Multiple Preclin
Strasbourg-Illkirch (also Design, Protein) Managing Dir.-CEO: Zeyer (Denis) [born 1972, Ph.D., ex-IGBMC]
  Key words: NHR (Nuclear Hormone Receptors), Ligands, Protein crystallography, Cancer, Type II diabetes, Obesity, Early-stage Sc.Dir.-CSO: Zeyer (Denis)
Mission: to discover, from early-stage, drugs based structure-based design using X-ray crystallography, with a main interest in nuclear hormone receptors, for cancers, type II diabetes, obesity and other metabolic diseases, also for neglected diseases such as schistosomiases, and to provide third parties with service activities in protein crystallization protein crystallography, and ligand screening using mass spectrometry Fin.Dir.-CFO:
www.alix-pharma.com Clients: Research labs BusDev:
Age: 18 year(s) Financers (Hist.): privately owned (registered capital 2006 = 0.07 M€)
Note: Alix has become, end of 2008, a subsidiary of Novalix, then Alix has been discontinued in 2009 ; no legal reports since 2006 for Novalix (and also Alix) ; Jenn (Stephan) [born 1968] is president of the company
NovoCIB 2005 Rhône-Alpes Contract, Research Personal venture | Virus Subcontractor
Lyon (also, Discovery, Drugs) Managing Dir.-CEO: Godard (Nicolas) [Ms. microbiology (INA), MBA]
  Key words: Nucleotides, Antivirals, HCV, Enzymes, Precice platform Sc.Dir.-CSO: Balakireva (Larissa) [founder, born 1966, Ph.D. Cell Biology, ex-IBS], also President
Mission: to provide third parties with a wide range of products and services, as nucleoside kinase phosphorylation assays, IMPDH or PNP inhibition assays, nucleotides and nucleosides bio-analysis, in cell extract or body fluids (including clinical samples) or the evaluation of the metabolic impact of compounds intended for therapeutic applications in oncology and virology or as immunosuppressive agents, and to develop own anti-viral nucleoside analogues Fin.Dir.-CFO:
www.novocib.com Clients: Pharmaceutical Industry, Biotechs BusDev:
Age: 15 year(s) Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€)
Novotec 1997 Rhône-Alpes Contract, Manufacturing Spin-off | Multiple Subcontractor
Lyon Key words: Antibodies, Extra cellular matrix (ECM), Tissue-samples, Immunochemistry, Histology Managing Dir.-CEO: Guerret (Sylviane) [born 1950] et Hartmann (Danielle) [born 1953]
  Mission: to develop, produce and distribute species specific antibodies directed against macro-molecules of the Extracellular Matrix (ECM), to prepare tissue analysis Sc.Dir.-CSO: Hartmann (Daniel)
Clients: Pharmaceutical industry, Cosmetic industry, Biotechs, Academic and Industry Research labs Fin.Dir.-CFO:
www.novotec-labs.com Age: 23 year(s) BusDev: Prulière (Franck)
Financers (Hist.): privately owned (registered capital 2006 = 0.065 M€)
Note: no communication policy on web site
Obe Therapy 2000 IDF Discovery, Targets Personal venture | Cardiovasc Preclin
Évry (also, Discovery,, Drugs) Managing Dir.-CEO:
  (near Paris) Key words: Gene targets, Intestine, Obesity, Hyper-cholesterolemia, Type II diabetes Sc.Dir.-CSO: Harosh (Itzik Isaac) [founder, born 1954, Ph.D., ex-GlaxoWelcome, CNRS, Technion (Israel)] and Braud (Sandrine) [also COO, Ph.D., ex-CEA, Institut Pasteur]
Mission: to discover new targets and to develop new drugs for obesity, hypercholesterolemia and type II diabetes, based on the identification of gene targets associated with a lean phenotype Fin.Dir.-CFO:
www.obetherapy.com Clients: Pharmaceutical industry BusDev:
Age: 21 year(s) Financers (Hist.): privately owned (registered capital 2006 = 0.06 M€)
Note: no communication policy on web site
Oligovax 2000 IDF Discovery, Immunology Start-up | Cancers Clinical
Paris Key words: Oligo-nucleotides, Immuno-stimulants, Cancer, Liténimod Managing Dir.-CEO: van der Schueren (Paul) [founder, born 1963, MBA]
  Mission: to develop innovative anti-cancer therapies belonging to a new therapeutic class, TLR9 agonists Sc.Dir.-CSO: Richard (Margaretha) [Pharm.D., ex-Pierre Fabre, AP-HP]
Clients: Prescribers Fin.Dir.-CFO:
www.oligovax.com Age: 20 year(s) BusDev:
Financers (Hist.): Global Millenium Fund
Communication: no website news update since 2006, no legal information available since end 2005
Note : webhosting with Lycos withdrawn in March 2009
Oncodesign 1995 Rhône-Alpes Contract, Research Personal venture | Studies Subcontractor
Dijon (also, Discovery, Therapies) Managing Dir.-CEO: Genne (Philippe) [co-founder, born 1961, Ph.D.]
  Key words: In-vivo screening, Nude-rat, Cancer, Drug resistance, Translational research, Neurology Sc.Dir.-CSO:
Mission: to provide third parties with preclinical evaluation of novel anticancer therapeutics and to identify and validate molecular targets involved in cancer pathologies Fin.Dir.-CFO:
www.oncodesign.fr Clients: Pharmaceutical industry BusDev: Ewing (Jonathan)
Age: 25 year(s) Financers (Hist.): CDC, Avenir Entreprise Gestion, Banque de Vizille
OriBase Pharma 2007 Méditerranée Contract, Research Personal venture | Studies Subcontractor
Montpellier Key words: Computational chemistry, Predictive-interpretative model building, QSAR/QSPR datamining, Structure-Activity relationships, SARA platform Managing Dir.-CEO: Yasri (Aziz) [co-founder, born 1966, Ph.D. biophysics and drug sciences, ex-Syntem, ArQule, J&J, Nova Decision]
  Mission: to provide third parties with medicinal chemistry oriented tools and services (chemo-informatics, molecular modelling and bio-informatics) from Hit Identification to Lead Optimisation Sc.Dir.-CSO: Yasri (Aziz)
Clients: Pharma industry, Agro industry, and Biotechs Chem.Dir.: Cazals (Bénédicte) [Ph.D. organic chemistry, ex-Idenix, Azasynth]
www.oribase-pharma.com Age: 13 year(s) I.T.Dir.: Chevé (Gwénaël) [Ph.D. medicinal chemistry, ex-Pierre Fabre]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned
Notes : in December 2010, the initial websites of the forming companies are still active under www.novadecision.com and www.azasynth.com ; foundation date of Oribase Pharma selected as that of Azasynth, i.e. only 1 month before Nova Decision
Oroxcell 2004 IDF Contract, Services (also, Delivery, Drug) Personal venture | Studies Subcontractor
Romainville Key words: Skin models (human), Pre-clinical testing, Drug delivery pre-formulation, Innovative formulations, Oral bioavailability Managing Dir.-CEO: Pachot (Jean) [founder, born 1960, Eng. biochemistry, ex-Roussel Uclaf, Aventis]
  (near Paris) Mission: to conduct preclinical studies (in vitro ADME, Animal PK on rodents, Phys-Chem testing, Bioanalysis) for third parties, plus to develop own research in cell culture and innovative formulations, financed by CRO cash-flow Sc.Dir.-CSO: Pachot (Jean)
Clients: Pharmaceutical industry, Research labs, Cosmetic industry, Food industry, Veterinary industry Chem.Dir.-CTO: Dini (Christophe) [born 1962, ex-Roussel Uclaf, Aventis]
www.oroxcell.com Age: 16 year(s) Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2007 = 0.3 M€)
Oxincell 2006 Méditerranée Contract, Services Personal venture | Virus Preclin
Montpellier Key words: Mitochondria, Oxymetry measurement, Toxicology, Antivirals Managing Dir.-CEO: Peyreigne (Christelle) [co-founder, born 1969, Ph.D. physiology, Inserm]
  Mission: to provide third parties with optimized oximetric analysis of mitochondrial activity Sc.Dir.-CSO:
Clients: Pharmaceutical industry, Biotechs, Research labs Fin.Dir.-CFO:
www.oxincell.com Age: 14 year(s) BusDev:
Financers (Hist.): privately owned
Communication: no website news update since 2006 in February 2010
Palumed 2000 Midi-Pyrénées Discovery, Drugs Personal venture | Infections Preclin
Toulouse Key words: Anti-malarial, Antibacterial, Covalent bi-therapy, Trioxaquines Managing Dir.-CEO: Meunier (Bernard) [born 1947, ex-Polytechnique (Professor), CNRS (President)]
  Mission: to develop new antimalarial agents and also new antibacterial molecules and chelating agents for the treatment of neurodegenerative diseases Sc.Dir.-CSO:
Clients: Pharmaceutical industry (Sanofi-Aventis) Fin.Dir.-CFO:
www.palumed.com Age: 20 year(s) BusDev: Meunier-Chesny (Claudine) [born 1949]
Financers (Hist.): IRDI, SOCRI, FCJE (CDC), GSO Capital, Viveris
PharmaLeads 2000 IDF Design, Drugs Personal venture | Multiple Trade
Paris (also, Discovery, Drugs) Managing Dir.-CEO: Bourbié (Thierry) [born 1952, Polytechnique-Mines, Ph.D. Geophysics, ex-Suez, Schlumberger]
  Key words: Enzymes, Zinc Metallopeptidases, Substrates, Inhibitors, Fluofast, Analgesia Sc.Dir.-CSO: Roques (Bernard Pierre) [Ph.D., ex-Inserm, Polytechnique (Assistant Prof.)]
Mission: to develop custom design of substrates and inhibitors of all types of proteases for three main applications, on-demand design of optimised substrates and/or inhibitors for pharmaceutical companies, internal drug discovery in the field of analgesia, leading services in botulinum toxin detection and assay Fin.Dir.-CFO: Maillard (Pierre) [MBA-ESSEC, ex-Dassault Aviation, Suez Environment]
www.pharmaleads.com Clients: Research labs, Pharmaceutical industry BusDev: Wurm (Michel) [M.D.]
Age: 20 year(s) Financers (Hist.): undisclosed
Pharnext 2007 IDF Delivery, Drugs Start-up | Orphan Clinical
Paris Key words: Drug Repositioning, Charcot Marie Tooth disease, Orphan drugs, Pleotherapy Managing Dir.-CEO: Cohen (Daniel) [co-founder, born 1951, Ph.D., ex-Genset, Millenium]
  Mission: to develop innovative treatments for serious neurological diseases, notably peripheral neuropathies (Charcot Marie Tooth, peripheral diabetic neuropathy), and possibly Alzheimer, by implementing a drug repositioning approach which aims to expand the indications for existing medicines Sc.Dir.-CSO: Chumakov (Ilya) [Ph.D. chemistry, D.Sc. Molecular Biology, ex-CEPH, Genset, Serono Genetics Institute
Clients: Prescribers Fin.Dir.-CFO: Heidsieck (Loïc) [ex-Arthur Young, Autologic, Franklin Mint, Serono, Genset]
www.pharnext.com Age: 13 year(s) BusDev:
Financers (Hist.): Truffle Capital, Aurinvest, Financière Boscary, Parinvest (Jean-Charles Naouri), Financière Gaspard
PhenoPro 2007 Alsace Contract, Services Spin-off | Studies Trade
Illkirch (also, Contract, Research) Managing Dir.-CEO: Schaeffer (Catherine) [born 1962]
  (near Strasbourg) Key words: Translational medicine, Mouse phenotyping, Targets Sc.Dir.-CSO:
Mission: to provide third parties with advanced mouse phenotyping-based translational medicine tools and expertise, in order to improve biopharmaceutical drug R&D productivity and patient access to safer and more efficacious drugs Fin.Dir.-CFO:
www.phenopro.com Clients: Research labs BusDev: Bocquel (François) [M.D., I.A.E., ex-Erudia, UCB Pharma, Parke Davis, Pfizer
Age: 13 year(s) Financers (Hist.): privately owned
Communication: no legal accounting information available since inception
Pherecydes Pharma 2006 IDF Discovery, Drugs Spin-off | Infections Preclin
Romainville Key words: Antibacterials, Phage genes, Emerging problems, Defense, Bio-threat, Libraries of bacteriophages Managing Dir.-CEO: Gabard (Jérôme) [born 1961, Ph.D., ex-Marketech, DuPont de Nemours]
  (near Paris) Mission: to develop, then to introduce new products against multi-resistance bacteria, combining surveillance, detection and therapeutic tools based on phage technology, as a bio-defense and bio-security company Sc.Dir.-CSO: Iris (François) [co-founder]
Clients: undisclosed R&D Dir.-CTO: Pouillot (Flavie) [Ph.D. Microbiology, ex-Institut Pasteur]
www.pherecydes-pharma.com Age: 14 year(s) BusDev:
Financers (Hist.): Biosecurity, Financière de Brienne
PolyIntell 2004 IDF-Normandy Contract, Research Personal venture | Studies Subcontractor
Val-de-Reuil (south Rouen) (also, Contract, Manufacture) Managing Dir.-CEO: Naraghi (Kaynoush) [co-founder, born 1970, Ph.D., Ms. management]
  Key words: Molecularly Imprinted Polymers, MIP, AFFINIMIP, Intelligent polymers, Selectivity, Solid phase extraction, Purification, Miniaturisation, Hydrogel, Sample preparation, Diagnostics Sc.Dir.-CSO: Bayoudh (Sami) [co-founder, Ph.D.]
Mission: to develop, manufacture and market more accurate analytical and diagnostic tools for pharmaceutical R&D and food safety, plus to operate own research in new polymers, financed by CRO cash-flow Oper.Dir.-COO: Arotçarena (Michel) [Ph.D.]
www.polyintell.com Clients: Pharmaceutical industry, Chemical industry, Food industry Fin.Dir.-CFO:
Age: 16 year(s) BusDev:
Financers (Hist.): privately owned
Proteogenix 2003 Alsace Discovery, Diagnostics Personal venture | Cancers Trade
Oberhausbergen (also Contract, Services) Managing Dir.-CEO: Funfrock (Philippe) [co-founder, born 1978]
  (near Strasbourg) Key words: Custom Antibodies, Recombinant proteins, Peptide synthesis, Gene synthesis, Cancer screening, Biomarkers Sc.Dir.-CSO: Hopfner (Raphaël)
Mission: to discover new diagnostic markers in cancer through targeted screenings and to provide third parties with polyclonal and monoclonal antibody development, recombinant protein production and purification, gene synthesis and peptide synthesis Fin.Dir.-CFO:
www.proteogenix-antibody.com Clients: Research labs BusDev:
Age: 18 year(s) Financers (Hist.): Oséo, privately owned
Note : Proteogenix will move in brand new state of the art facilities by 2011
Protexel 2000 IDF Discovery, Drugs Spin-off | Liver Clinical
Paris Key words: Immunology, Alcoholic hepatitis, Liver cancer, Cirrhosis, Chemical mimetics, Anti-oxydant, Superoxyde dismutase, Mangafodipir Managing Dir.-CEO: Batteux (Frédéric) [Batteux (Arman), born 1939, legally as President]
  Mission: to develop innovative treatments for severe liver conditions Sc.Dir.-CSO:
Clients: Pharmaceutical industry (own development up to phase III) Fin.Dir.-CFO:
www.no-website.net Age: 20 year(s) BusDev:
Financers (Hist.):
Note : no Company website since inception
PX’Therapeutics 2000 Rhône-Alpes Contract; Research Personal venture | Multiple Trade
Grenoble (also, Contract, Manufacturing) Managing Dir.-CEO: Rousselle (Tristan) [co-founder, born 1970, Ph.D. cellular biology]
  Key words: Recombinant protein engineering Sc.Dir.-CSO: Mouz (Nicolas) [co-founder, born 1966, Ph.D. molecular biology]
Mission: to develop biotherapeutics (valuable recombinant proteins) from early stage research up to cGMP production through its specialized technology and manufacturing platforms Protein’eXpert, PX’Monoclonals and PX’Pharma, for third parties Prod.Dir.-CTO: Mouz (Sebastien) [Ph.D.]
www.px-therapeutics.com Clients: Pharmaceutical industry, Biotechs Fin.Dir.-CFO:
Age: 20 year(s) BusDev: Untereiner (Claire)
Financers (Hist.): Vizille Capita (and others), privately owned (registered capital 2007= 0.13 M€)
Quantum Genomics 2006 IDF Discovery, Drugs Start-up | Multiple Preclin
Massy Key words: Academic, Development platform, Co-partnering R&D Managing Dir.-CEO: Segard (Lionel) [born 1968, Biochemistry, ex-Inserm-Transfert (CEO), IBM, TFSM]
  (near Paris / HQ Mission: to maximize the developments and discoveries of academic research into breakthrough treatments for human disease, in cardiovascular diseases, neurology and metabolic related diseases Sc.Dir.-CSO: Riffaud (Jean-Pierre) [Pharm.D., ex-Cellpep, NicOx, Fournier, Debat]
Jersey City Clients: Pharmaceutical industry Fin.Dir.-CFO:
www.quantum-genomics.com USA) Age: 15 year(s) BusDev:
Financers (Hist.):
Rhenovia Pharma 2007 Alsace Contract, Research Personal venture | CNS Proof-of-Concept
Mulhouse Key words: Alzheimer, Biosimulation, Computational neuroscience, Memory Managing Dir.-CEO: Bischoff (Serge) [co-founder, born 1948, Ph.D. neuropharmacology, ex-Novartis]
  Mission: to contribute to discover new medicines against Alzheimer’s and other central nervous system (CNS) diseases, by developing breakthrough biosimulation platforms for memory and other CNS functions Sc.Dir.-CSO: Baudry (Michel) [co-founder, born 1948, Eng. Ecole Polytechnique, Prof. engineering (Los Angeles), Ph.D.]
Clients: Pharmaceutical industry, Biotechs Oper.Dir.-COO: Faupel (Michel) [co-founder, ex-Novartis]
www.rhenovia.com Age: 13 year(s) Fin.Dir.-CFO:
BusDev: George (Florian) [Ph.D. chemistry]
Financers (Hist.): privately owned, no outisde investors (registered capital 2007 = 0.126 M€)
ScarCell Therapeutics 2007 IDF Design, Drugs Spin-off | Cardiovasc Proof-of-Concept
Paris Key words: Cell therapy project, Transplantation, Cardiovascular Managing Dir.-CEO: Augier (Jean-Jacques) [legally as President, born 1953]
  Mission: to carry out an autologous gingival fibroblasts transplantation in order to repair injured tissues, in particular in the field of cardiovascular pathology (vascular prosthesis for abdominal aortic aneurysm, atherosclerosis,…) and others Sc.Dir.-CSO:
Clients: undisclosed Fin.Dir.-CFO:
www.scarcell-therapeutics.com Age: 13 year(s) BusDev:
Financers (Hist.):
Note : URL not renewed in time (October 2009), still unavailable (February, May, October 2010, April 2011, December 2012), but legally company still active (with a new President since July 2012, Laurent Cezard, born March 1969
Sisène Biotechnologies 2007 IDF Discovery, Drugs Academic | Cancers Preclin
Paris Key words: Cancer, Vegf, Anti-angiogenics, Ophtalmology Managing Dir.-CEO: Marsac (Jean) [born 1943, co-founder, M.D., Professor]
  Mission: to discover and develop new anti-angiogenic biotherapies, in cancers and ophtalmology Sc.Dir.-CSO: Plouët (Jean) [deceased, co-founder, M.D., Ph.D., Professor, Inserm, ex-Abtech, Gencell, AP-HP Lariboisière]
Clients: Pharmaceutical industry (own development up to clinical trials) Oper.Dir.-COO: Garreau (Martine) [born 1951, M.D., ex-Synthelabo]
www.no-website.net Age: 13 year(s) Fin.Dir.-CFO:
BusDev:
Financers (Hist.): ARC, ANR, InCA
Note (November 2011) : the new company website is available
Skuld-Tech 1999 Méditerranée Design, Diagnostics Spin-off | Multiple Preclin
Montpellier (also, contract, research) Managing Dir.-CEO: Ritter (Didier) [co-founder, born 1969, Ms. molecular biology, MBA, ex-Bio2R (founder)]
  Key words: Biomarkers, Genomics, Pharmaco-genomics, Bio-informatics, Biosensors, SAGE Sc.Dir.-CSO: Piquemal (David) [co-founder, Ph.D., Prof. genomics]
Mission: to select and validate biomarkers, bioinformatics, biosensors, leading to design new diagnosis, identify new targets, and generate new leads for biopharmaceutical companies and personalized medicine Fin.Dir.-CFO: Outrebon (Philippe) [co-founder, Ms. sciences, ex-Ernst & Young]
www.skuldtech.com Clients: Research labs BusDev: Outrebon (Philippe)
Age: 21 year(s) Financers (Hist.): Oseo, Regional Territory Body, Private Investors
Stentys 2006 IDF Design, Devices Start-up | Cardiovasc Trade
Paris Key words: Stent, Heart-Attack, Revascularisation, Managing Dir.-CEO: Issenmann (Gonzague) [co-founder, born 1972, MBA, ex-CordisJ&J]
  Mission: to develop a new generation of self-expanding stents or self-apposing stents, specialized in the treatment of heart attacks (or Acute Myocardial Infarction) Sc.Dir.-CSO:
Clients: Device Industry, Hospitals Med.Dir.: Spaargaren (René) [M.D., Medtronic, Boston Scientific, EV3]
www.stentys.com Age: 14 year(s) Mktg&Sales: Goffart (Lucien) [MBA, ex-J&J, Abbott , Volcano]
Fin.Dir.-CFO: Piot (Stanislas) [Ms. finance and economics, ex-Ipsogen, Banque Worms, Crédit Lyonnais, Oddo, Natixis]
BusDev:
Financers (Hist.): Sofinnova Partners, Scottish Equity Partners, Crédit Agricole Private Equity, FSI, Public (registered capital 2009 = 0.16 M€)
Synapcell 2005 Rhône-Alpes Contract, Research Personal venture | CNS Subcontractor
Grenoble Key words: Preclinical development, CNS, Epilepsy, Neuronal networks Managing Dir.-CEO: Roucard (Corinne) [born 1969, co-founder, Ph.D., ex-Synapcell (Project Leader)]
  Mission: to provide third parties with customized solutions for preclinical evaluation of CNS therapeutics and with consulting, pre-designed and customized programs to expertise drug candidates of the biopharmaceutical industry, and also to develop own research innovative tools Sc.Dir.-CSO: Bressand (Karine) [born 1971, Ph.D.]
Clients: Research labs Fin.Dir.-CFO: Roche (Yann) [born 1974, Ph.D. biology, Ms. Management]
www.synapcell.com Age: 15 year(s) BusDev: Roche (Yann)
Financers (Hist.): privately owned (registered capital 2006 = 0.09 M€)
Synprosis 2003 Méditerranée Discovery, Immunology Personal venture | Vaccines Preclin
Fuveau (also Contract, Manufacturing) Managing Dir.-CEO: Salles (Jean-Pierre) [born 1954, Pharm.D., ex-Laphal (Dir. R&D)]
  (near Marseille) Key words: HIV1 vaccine, Synthetic peptides Sc.Dir.-CSO:
Mission: to provide custom peptide synthesis (notably vaccines) in solid phase manufacture with high quality for basic research and for therapeutic applications (cGMP) and to develop own immunological compounds Fin.Dir.-CFO:
www.synprosis.com Clients: Pharmaceutical industry BusDev: Pomarède (Richard)
Age: 17 year(s) Financers (Hist.): privately owned (registered capital 2007 = 0.23 M€)
Tc Land Expression 2002 Bretagne Design, Diagnostics Spin-off | Multiple Preclin
Nantes Key words: Biomarkers, Transplantation, Auto-immune diseases Managing Dir.-CEO: Tchelingerian (John) [born 1965, Ph.D. neuroscience, ex-Neurotech (co-founder), Key Obs (co-founder), Diatos (CEO)]
  Mission: to develop gene expression biomarkers in transplantation and immunology through proprietary strategy of personalized medicine Sc.Dir.-CSO: Guillet (Marina) [born 1973, Ph.D., ex-TcLand (CEO)]
Clients: Pharmaceutical industry, Research labs Clin.Dir.-CMO: Larcier (Patrick) [Pharm.D., MBA Essec, ex-Neovacs, Biogen-Idec, Quintiles, Parexel, GSK]
www.tcland-expression.com Age: 18 year(s) Fin.Dir.-CFO: Jaffré (Philippe) [MBA, ex-Novartis, Chiron, Dana Capital]
SalesMktg: Kazek (Elodie) [Pharm.D., ESSEC, ex-BioMerieux, Fresenius Kabi, Merck KgAa]
BusDev: Payne (Peter) [Ms. pharmacology, ex-Quintiles, Wellcome, Sterling Drug, Glaxo], also Head of US-Business
Financers (Hist.): Auriga Partners, Debiopharm, Genzyme Ventures, Quest For Growth, Beviguen
Note: the previous URL, tcland-biotech.com, has been replaced by tcland-expression.com, late 2010
Theraclion 2004 IDF Development, Devices Start-up | Multiple Clinical
Paris Key words: Ultrasound, Parathyroidism, Prostate cancer, Fibroadenoma, UNIS Managing Dir.-CEO: Burel (Jean-Yves) [born 1951, ex-GE Healthcare]
  Mission: to develop non-invasive solutions, based on High Intensity Focussed Ultrasound (HiFu), for the non-invasive ablation of small tumors and the treatment of secondary hyperparathyroidism, thyroid nodules Sc.Dir.-CSO: Lacoste (François) [co-founder, born 1950, Eng. physics, ex-Technomed, Cilas-Alacatel, Perkin Elmer]
Clients: undisclosed R&D Dir.-CMO: Yon (Sylvain) [born 1974, ESCPI, Ph.D. physics, ex-Echosens (co-founder)]
www.theraclion.fr Age: 16 year(s) Fin.Dir.-CFO:
BusDev: Del Bourgo (David) [Eng. UIT Compiègne, MBA Chicago, ex-Orbotech, Advention Business Partners, General Electric Healthcare]
Financers (Hist.): Truffle Ventures
Theradiag 1987 IDF Discovery, Diagnostics Start-up | Allergy Trade
Marne-la-Vallée (also, Design, Devices) Managing Dir.-CEO: Finance (Michel) [Ms. EM Lyon, ex-Neovacs, Carmat, Flamel Technologies, Aventis]
  (near Paris) Key words: Auto-immune diseases, Allergy test monitor, Caris, Fidis, Luminex Tech.Dir.-CTO: Parussini (Ermis), Ms.Sc. molecular biology, ex-Biomérieux
Mission: to develop, manufacture and market quality and innovative IVD products for the diagnostic market of auto-immune diseases, allergies and infectious diseases Sc.Dir.-CSO:
www.theradiag.com Clients: Pharmaceutical industry Sales Dir.: Sallen (Eric), Abbott, Becton Dickinson, Saint Gobain, Kottermann, Seroa]
Age: 33 year(s) Admin.Dir.: François (Fabienne) [MBA, HR experience]
BusDev:
Financers (Hist.): Truffle Venture (majority share), CDC Entreprise, AGF P.E., Siparex, Auriga Partners, Ventech, 123 Multinova
Communication:with company name change, the URL moves and www.bmd-net.com is deleted (June 2012)
Theralpha 2009 Méditerranée Discovery, Drugs Spin-off | Pain Preclin
Sophia Antipolis Key words: Pain, Acid-Sensing-Ion-Channel (ASIC), Sublingual Managing Dir.-CEO: Dellamonica (David) [ESG, MBA, ex-TxCell, Nex&Com, Polygram Universal, Ogilvy Healthcare]
  (near Nice) Mission: to develop innovative peptide-based drugs for the treatment pain Sc.Dir.-CSO: Lazdunski (Michel) [Ph.D., Professor, CNRS]
Clients: Pharmaceutical industry (own development up to clinical trials) Fin.Dir.-CFO:
www.theralpha.com Age: 11 year(s) BusDev:
Financers (Hist.): privately owned (registered capital 2009 = 0.04 M€)
TheraVectys 2005 IDF Discovery, Immunology Spin-off | Vaccines Preclin
Paris Key words: Vaccines, DNA Flap Lentivirus, Veterinary Managing Dir.-CEO: Gohaud (Romain) [born 1949]
  Mission: to develop new vaccines derived from the DNA Flap Lentivirus technology Sc.Dir.-CSO: Charneau (Pierre) [Ph.D. virology, Institut Pasteur]
Clients: Pharmaceutical industry (own development up to clinical trials) Fin.Dir.-CFO:
www.theravectys.com Age: 15 year(s) BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.06 M€)
Transgene 1979 Alsace Discovery, Immunology Start-up | Vaccines Clinical
Strasbourg Key words: Therapeutic vaccines, Immuno-therapy, Cancer, Infectious diseases Managing Dir.-CEO: Archinard (Philippe) [born 1959, Ph.D. Biochemistry, Eng. Chemistry, ex-Innogenetics (CEO), Biomérieux]
  Mission: to discover and develop gene-based therapeutic vaccines and immunotherapy products Sc.Dir.-CSO: Bonnefoy (Jean-Yves) [Ph.D. immunology, ex-Pierre Fabre, Glaxo Wellcome]
Clients: Prescribers Med.Dir.-CMO: Adda (Nathalie) [M.D., ex-Vertex]
www.transgene.fr/us Age: 42 year(s) Fin.Dir.-CFO: Boissel (Stéphane) [MBA (Chicago), ex-PWC, Innate Pharma, Lazard]
BusDev:
Financers (Hist.): Mérieux (53%), Institutional investors, AFM, Public
Trophos 1999 Méditerranée Discovery, Drugs Personal venture | Multiple Clinical
Marseille Key words: Embryonic neurones, Parkinson’s diseases, Huntington’s diseases, Cardiac ischemia, IRIstop Managing Dir.-CEO: Placet (Christine) [Sup de Co (Marseille), ex-Ernst & Young]
  Mission: to develop drugs to prevent neuronal loss in patients with neurodegenerative diseases, based on proprietary screening system employing sick neurons (focused in 2009, onto neuroprotection and cardioprotection) Sc.Dir.-CSO: Pruss (Rebecca) [Ph.D., ex-Sanofi-Synthélabo]
Clients: Prescribers Med.Dir.-CMO: Abitbol (Jean-Louis) [M.D., ex-Parke Davis, Pfizer, Pierre Fabre]
www.trophos.com Age: 22 year(s) Fin.Dir.-CFO:
BusDev: Harris (Stephen) [Ph.D., ex-GSK]
Financers (Hist.): Société Générale Assets Management (SGAM), Turenne Capital Partners, Viveris Management, SOFIPACA, SOFIMAC OTC Asset Management, CM-CIC Asset Management, Blue Medical, AFM (French Muscular Dystrophy Association), Innoveris, business angels
TxCell 2001 Méditerranée Discovery, Immunology Spin-off | Inflammation Clinical
Sophia Antipolis Key words: Cell Therapy, Inflammatory, Autoimmune diseases Managing Dir.-CEO: Meyer (François) [born 1948, Ph.D. molecular biology, ex-Ciba-Geigy, Sandoz, Rhone Poulenc Rorer, Aventis]
  (near Nice) Mission: to develop new therapies to cure inflammatory and autoimmune diseases, such as Crohn’s disease, multiple sclerosis, psoriasis or rheumatoid arthritis, by bringing regulatory T cells to the body Sc.Dir.-CSO: Foussat (Arnaud) [Ph.D., ex-Inserm]
Clients: Prescribers Med.Dir.-CMO: Forte (Miguel) [M.D., Ph.D., ex-B.M.S., Nabi Pharmaceuticals, UCB]
www.txcell.com Age: 19 year(s) Fin.Dir.-CFO: Sarlot (Christophe)
BusDev:
Financers (Hist.): Auriga Partners, AXA Private Equity, BioAm, CDC, SPEF Venture, Inserm-Transfert
UROsphere 2004 Midi-Pyrénées Contract, Research Spin-off | Multiple Preclin
Labège Key words: Urinary incontinence, Benign prostatic hyperplasia (BPH), Sexual dysfunctions, Renal disorders Managing Dir.-CEO: Lluel (Philippe) [born 1966, Ph.D. pharmacology]
  (near Toulouse) Mission: to provide third parties with research preclinical services for urology and renal pathologies Sc.Dir.-CSO: Palea (Stefano) [born 1962, Ph.D. pharmaceutical chemistry, ex-Sanofi-Aventis, Glaxo-Wellcome]
Clients: Pharmaceutical industry Fin.Dir.-CFO:
www.urosphere.com Age: 16 year(s) BusDev:
HR.Dir: Mignotte-Darmon (Brigitte) [DESS Management]
Financers (Hist.): privately owned (registered capital 2006 = 0.13 M€)
note (March 2010) : new website unveiled
Vaxon Biotech 2004 IDF Discovery, Immunology Personal venture | Vaccines Clinical
Paris Key words: Therapeutic vaccines, Cryptic peptides Managing Dir.-CEO: Vallet (François) [born 1958, Polytechnique, Ph.D. physics, ex-Genewave (co-founder)]
  Mission: to develop innovative therapeutic vaccines for the treatment of cancer including lung, prostate, breast, renal, liver and colorectal cancer, using proprietary technology of optimized cryptic peptides Sc.Dir.-CSO: Kosmatopoulos (Kostas) [born 1950, M.D., Ph.D., also Chairman, ex-Inserm]
Clients: Prescribers Fin.Dir.-CFO:
www.vaxon-biotech.com Age: 17 year(s) BusDev:
Financers (Hist.): Génopole 1er Jour (G1J), Inserm-Transfert, privately owned
Vectalys 2005 Midi-Pyrénées Design, Drugs Personal venture | Virus Preclin
Labège (also, Contract, Resarch) Managing Dir.-CEO: Bouillé (Pascale) [born 1967, founder, Ph.D. molecular biology, secretary JEInnov]
  (near Toulouse) Key words: Gene sequences, Gene transfer, Viral vector, Retrovirus, Lentivirus Sc.Dir.-CSO:
Mission: to provide third parties with a platform of retroviral (RV), lentiviral (LV) and adeno-associated virus (AAV) based vectors that efficiently introduce human gene sequences into a wide variety of human cells to knock-in or knock-down specific proteins Fin.Dir.-CFO:
www.vectalys.com Clients: Pharmaceutical industry BusDev:
Age: 15 year(s) Financers (Hist.): pricately owned (registered capital 2006 = 0.05 M€)
Vivalis 1999 Bretagne Design, Manufacture Start-up | Multiple Preclin
Nantes (also, Discovery, Immunology) Managing Dir.-CEO: Grimaud (Franck) [co-founder, born 1966, MBA]
  Key words: Vaccines, Flu, Viral diseases, EBx Cell line, Therapeutic protein, Cell Culture, EB66 Sc.Dir.-CSO: Mehtali (Majid) [Ph.D., ex-Deltagen, Transgene, Rhône Mérieux]
Mission: to provide innovative cell-based solutions for the industrial manufacture of viral vaccines and therapeutic proteins, and to develop own vaccines and drugs in order to prevent and treat viral diseases (also deeply involved in veterinarian vaccines) Fin.Dir.-CFO: Rousseau (Philippe) [HEC, ex-Exonhit, Valigen, Genset, Mars, Paribas]
www.vivalis.com Clients: Pharmaceutical industry (own development up to clinical trials) BusDev: Miniou (Pierre) [Ph.D., ex-Pierre Fabre, Transgene]
Age: 21 year(s) Financers (Hist.): Grimaud-La Corbière Group, Public
Note : company legal domiciliation : Roussay (49)
XenTech 2006 IDF Contract, Research Spin-off | Cancers Preclin
Évry (also, Discovery, Diagnostics) Managing Dir.-CEO: Coulomb (Bertrand) [born 1955, Pharm.D., ex-Nycomed, Altana Pharma, Pasteur-Sanofi Diagnostics, UPSA (BMS), Servier]
  (near Paris) Key words: Theranostics, Preclinical oncology, Tumor models Sc.Dir.-CSO: Judde (Jean-Gabriel) [co-founder, born 1954, Ph.D., ex-MD Anderson Cancer Center, NCI, Institut Curie, also board chairman]
Mission: to provide specialized services in predictive preclinical oncology, to develop own treatment diagnostics derived from patient-derived tumor xenografts Oper.Dir.-COO: Leuraud (Pascal) [co-founder, Ph.D.]
www.xentech.eu Clients: Pharmaceutical industry, Biotechs, Research labs Fin.Dir.-CFO:
Age: 14 year(s) BusDev: Bazzacco (Paola)
Financers (Hist.): privately owned (registered capital 2007 = 0.05 M€), Aurinvest Capital 2